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Abstract 
 
The promiscuous xenobiotic receptor (PXR, NR1I2, also denoted pregnane X receptor) is a 
nuclear receptor which regulates the transcription of genes involves in the biotransformation 
of endogenous and xenobiotic compounds. PXR is activated by ligands including steroids, 
natural products, as well as drugs and pollutants, making it an important subject of research 
in a pharmacological and ecotoxicological context. One method of studying this nuclear 
receptor is through the use of high quality, specific antibodies which can immunochemically 
detect the protein. In the first part of this study, the immunoreactivity of hybridoma 
supernatants obtained from cells of mice immunised with either human PXR (hPXR, Homo 
sapiens) or zebrafish Pxr (zfPXR, Danio rerio), suspected to contain monoclonal antibodies 
specific to each PXR ortholog, were tested against eukaryotically expressed hPXR and 
zfPXR, as well as prokaryotically expressed zfPXR. Hybridoma supernatants from mice 
immunised with hPXR were found to be immunoreactive against the hPXR antigen, however 
some of these supernatants were immunoreactive with an additional protein that was heavier 
than the PXR antigen. Hybridoma supernatants from mice immunised with zfPXR were not 
found to be immunoreactive against either eukaryotically or prokaryotically expressed zfPXR 
antigen. In a second aspect of this study, research has identified allelic variants in the amino 
acid sequence of zfPXR and this could have implications on the nuclear receptor’s ability to 
function. A method for extracting RNA from individual zebrafish embryos was established in 
our laboratory, and pxr was sequenced from individuals (n = 24). However no genetic 
variation was found in this sample set, compared to what has been identified in literature and 
to online databases. 
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1. Introduction 
 
1.1 Background 
The promiscuous xenobiotic receptor (PXR, NR1I2) is a nuclear receptor which is 
responsible for regulating genes involved in the biotransformation of endogenous and 
xenobiotic compounds (Blumberg et al., 1998). When activated by ligands, PXR induces the 
transcription of genes which encode for enzymes involved in xenobiotic and steroid 
metabolism. Mammalian PXR is also known as the pregnane X receptor and steroid and 
xenobiotic sensing receptor (SXR), while the chicken and frog orthologs are chicken X 
receptor (CXR) and benzoate X receptor (BXR), respectively (Milnes et al., 2008). 
 
1.2 Nuclear receptors 
1.2.1 Nomenclature, types and function 
There are seven subfamilies of nuclear receptors and according to sequence similarity, PXR 
is placed in the nuclear receptor subfamily 1 group I member 2 (Nuclear Receptors 
Nomenclature Committee, 1999; Laudet, 1997). PXR is most closely related to the vitamin D 
receptor (VDR, NR1I1) and constitutive androstane receptor (CAR, NR1I3), which can be 
activated by calcitriol and steroids respectively (Krasowski et al., 2011). These three nuclear 
receptors also belong to the thyroid-like receptors subfamily, which includes the thyroid 
hormone receptor (TR, NR1A), retinoic acid receptor (RAR, NR1B), peroxisome 
proliferator-activated receptor (PPAR, NR1C1, 1C2 and 1C3), liver X receptor (LXR, 
NR1H2 and 1H3) and the farsenoid X receptor (FXR, NR1H4 and 1H5) which are involved 
in other important processes in the body such as development, homeostasis, metabolism and 
bile acid synthesis (Robinson-Rechavi et al., 2003; Germain et al., 2006). 
 
This thesis follows protein and gene nomenclature guidelines according to the Genetics and 
Molecular Biology journal. In humans and mammals, the protein form of NR1I2 is written as 
PXR; and as Pxr in zebrafish. The gene is written as PXR in humans; in mice it is written as 
Pxr; and as pxr in fish. 
 
1.2.2 Nuclear receptor evolution 
It has been proposed that the first nuclear receptor developed in metazoans over 600 million 
years ago (Escriva et al., 2000), and ability for ligands to activate receptors occurred later in 
evolution (Escriva et al., 1997). These first receptors were classified as orphan receptors, 
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because they either lacked an exclusive endogenous ligand or one had not yet been identified. 
Today, nuclear receptors are considered promiscuous to a wide range of endogenous and 
exogenous compounds, depending on which group they belong (Krasowski et al., 2011). 
 
1.3 Promiscuous xenobiotic receptor, PXR 
1.3.1 Induction of cytochrome P450 monooxygenases 
One important group of genes regulated by PXR is the cytochrome P450 (CYP) 
monooxygenases, and these represent enzymes involved in the oxidation of steroids and 
xenobiotic compounds in phase I biotransformation. CYP activity occurs mostly in the liver, 
small intestine and colon, where the highest level of xenobiotic detoxification takes place 
within the body (Bertilsson et al., 1998; Nishimura et al., 2004; Lamba et al., 2004). CYP 
enzymes are divided into family, subfamily and gene number, and are an important enzyme 
group since they metabolise almost 75% of drug reactions (Figure 1.1; Nelson et al., 1996; 
Guengerich, 2008). One important subfamily of CYP enzymes regulated by PXR activation 
in humans are the CYP3A4 enzymes, which have been said to metabolise about 50% of 
pharmaceutics (Guengerich, 2008). In zebrafish, Pxr is known to induce cyp3a65 upon 
activation (Tseng et al., 2005; Bresolin et al., 2005). 
 
 
Figure 1.1. A pie chart depicting the percentage enzymes contribute to the metabolism of the top 
200 prescribed drugs in the United States from 2002. A) The cytochrome P450 enzyme superfamily 
contributes to nearly 75% of drug metabolism; and B) The 3A subfamily contributes to almost 50%. 
Figure taken from Guengerich (2008). 
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1.3.2 Other roles of PXR 
Apart from mediating CYP hydroxylation in phase I biotransformation, PXR has also been 
shown to induce the expression of other important genes involved in different stages of the 
detoxification process. For example, PXR can induce the transcription of conjugating 
enzymes UDP-glucuronsyltransferase (UGT) and sulphotransferase (SULT) in phase II 
biotransformation (Sonoda et al., 2002; Rae et al., 2001), and regulate the uptake and efflux 
of compounds through ATP-binding cassette (ABC) transporters in phase III 
biotransformation, including the multidrug resistant protein 1 (MDR1) and the multidrug 
resistance-associated protein 2 (MRP2) (Synold et al., 2001; Kast et al., 2002). PXR also 
plays an important role in lipid homeostasis (Dussault et al., 2003; Sonoda et al., 2005), and 
is known to interact with other steroid receptors, including CAR and FXR (Jung et al., 2006; 
Xie et al., 2000). 
 
1.3.3 Ligand interaction 
PXR has broad ligand specificity, meaning that it can become activated by a range of 
compounds. PXR is activated by endogenous compounds such as bile acids and steroid 
metabolites such as progesterone, oestrogen and corticosterone (Xie et al., 2001; Kliewer et 
al., 2002). PXR can also be activated by exogenous compounds, which include natural 
products such as St. John’s wort, sulphoraphane, and vitamin E and K (Moore et al., 2000; 
Zhou et al., 2007; Landes et al., 2003; Tabb et al., 2003). These compounds are important 
when considering their combined effects with drug intake, since many of the PXR-related 
pathways associated with these products are also shared with pharmaceuticals. 
 
This means that pharmaceutics also play an important role in the activation of PXR. Drugs 
such as rifampicin, RU486, taxol, SR12813 and ET-743 are all capable of regulating the 
activity of PXR (reviewed by Kliewer et al., 2002). Most of these drugs are agonists, i.e. 
activators of PXR, whereas fewer compounds (e.g. ET-743) are antagonists, i.e. inhibitors of 
PXR. The degree of activation or inhibition largely depends on the compound’s affinity 
towards PXR, meaning that different compounds will activate PXR more strongly than others 
and this has also been shown to vary between species (Lehmann et al., 1998; Milnes et al., 
2008). For example, rifampicin has been shown to be a strong activator of PXR in human and 
rabbit, but not in rat or mouse (Jones et al., 2000). This often makes it challenging to predict 
the degree to which a compound can activate PXR across species when deciding which 
model species to use (Milnes et al., 2008). 
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1.3.4 Pollutants as ligands 
The World Health Organization (2002) defines endocrine-disrupting compounds (EDCs) as: 
“an exogenous substance or mixture that alters function(s) of the endocrine system and 
consequently produces adverse health effects in an intact organism, or its progeny, or 
(sub)populations”. EDCs have 3 modes of action: 1) compounds can act as hormone mimics, 
exhibiting either agonistic or antagonistic effects; 2) compounds can interfere with natural 
hormone pathways; and 3) compounds can interfere with the production and function of 
hormone receptors (Rotchell and Ostrander, 2003; Goksøyr, 2006). Because PXR is 
susceptible to a broad range of ligands, this means that EDCs are also be capable of 
activating this receptor. In mice, EDCs including phthalic acid and nonylphenol have been 
shown to activate PXR (Masuyama et al., 2000). In humans, EDCs such as organophosphates, 
polychlorinated biphenyls (PCBs) (reviewed in Zhou et al., 2009), brominated flame 
retardants (BFRs) (Pacyniak et al., 2007), and bisphenol A (BPA) have all been shown to 
activate PXR (Sui et al., 2012). 
 
Studying the effects of pollutants as xenobiotics is an important aspect of toxicology. Many 
pollutants have been screened across PXR orthologs by studying their ability to activate the 
nuclear receptor (Milnes et al., 2008; Kojima et al., 2011). One common method for testing 
this is to clone the gene which encodes PXR and using recombinant expression to incorporate 
the transcript into a vector for transfection into a eukaryotic cell line. The luciferase assay is 
one way that toxicologists can test ligand activation in nuclear receptors (Grün et al., 2002; 
Milnes et al., 2008), and is a current focus in toxicological research. 
 
1.3.5 Localisation of PXR 
For humans, PXR is found in most cells but is localised mostly in the liver and small intestine, 
where the majority of steroid and xenobiotic metabolism takes place in the body (Blumberg 
et al., 1998). However, the nuclear receptor has been shown to be expressed in the lungs and 
kidney (Miki et al., 2005), bone (Tabb et al., 2003) and even immune cells (Siest et al., 2008; 
Dubrac et al., 2010). The subcellular localisation of PXR is currently disputed (reviewed by 
Zhou et al., 2009), and its exact location in the presence or absence of ligand varies according 
to species and even study (Saradhi et al., 2005; Squires et al., 2004; Koyano et al., 2004). 
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1.3.6 Structure 
Most nuclear receptors contain a modular structure that consists of domains labelled A to F, 
corresponding to the N and C terminals respectively (Figure 1.2). These include the DNA 
binding domain (DBD, C), the flexible hinge region (D) and the ligand binding domain (LBD, 
E) (Kumar and Thompson, 1999). Within the N-terminal is activation function 1 (AF-1), 
which is usually ligand independent, as opposed to activation function 2 (AF-2) found within 
the LBD, which is dependent on the presence or absence of ligand. 
 
When PXR is activated by ligands, dimerisation of the nuclear receptor occurs at both the 
DBD and LBD. The DBD contains two zinc fingers which allow the transcription factor to 
bind to a target gene’s xenobiotic or hormone response element (XRE / HRE). This response 
element is located in the promoter region of the target gene, and contain motifs recognised by 
the nuclear receptor which help regulate transcription (Goodwin et al., 2002; Song et al., 
2004).  The LBD binds to RXR, which helps promote transcription of the target gene. 
 
 
Figure 1.2. Modular structure of nuclear receptors, divided into its domains from the N to C 
terminals (A to F). The nuclear localisation signal (NLS) is located within the DBD (C) and hinge 
(D) domains. Figure modified from Escriva et al. (2000). 
 
 
In humans, full length PXR protein is 434 amino acids long and has a molecular weight of 
approximately 50 kD. While the complete crystal structure of PXR has yet to be determined, 
the LBD of PXR is known to some extent (reviewed in Wu et al., 2013). The LBD in PXR 
contains a flexible, hydrophobic and large ligand binding pocket (LBP), which has a low 
binding affinity with most ligands. The LBP has also been shown to interact with the same 
ligand in different conformations and in a different way to most other types of nuclear 
receptors (Watkins et al., 2001; Xue et al., 2007). 
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1.4 Variation in PXR orthologs 
1.4.1 Species-specific variation 
While the DBD in PXR is generally well conserved across species (Kliewer et al., 2002), the 
LBD however has been shown to be poorly conserved (Moore et al., 2002). Figure 1.3 shows 
how the amino acid sequence varies between species. Because of these differences, activation 
of PXR orthologs by the same ligand can lead to different levels of transcriptional response. 
For example, single amino acid differences in the LBD between human and mouse PXR have 
led to differences in its activation after ligand exposure (Östberg et al., 2002). 
 
 
Figure 1.3. Amino acid sequence identity of PXR between humans and other species. 
 
 
1.4.2 Genetic variation 
1.4.2.1 Human PXR 
The human PXR gene is 35 kilobases (kb) in length and is located on chromosome 3 (13q12-
13.3). It consists of nine exons that when transcribed, give a coding sequence of 1305 base 
pairs (bp). Single polynucleotide polymorphisms (SNPs) are known to occur in the coding 
region of the human PXR sequence, whereby a single nucleotide is substituted with another. 
This leads to either a non-synonymous (amino acid change) or synonymous (amino acid 
remains the same) variants in the amino acid sequence. Fifteen of these SNPs in human PXR 
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are non-synonymous (Figure 1.4; Zhou et al., 2009) and these are located throughout the 
sequence. One of these variants located on the DBD (R98C) has been shown to fail to both 
bind to the XRE and induce CYP3A4 (Koyano et al., 2004). SNPs located on the LBD have 
also been shown to affect human PXR (hPXR) activation and CYP3A4 transcriptional 
response (reviewed in Zhou et al., 2009). 
 
 
Figure 1.4. A modular structure of the coding region of human PXR including the DBD and LBD. 
The location of the fifteen known non-synonymous SNPs and their associated amino acid 
substitutions are indicated by *. Figure adapted from Zhou et al. (2009). 
 
 
1.4.2.2 Zebrafish Pxr 
The zebrafish pxr gene is 96.5 kb long and is located on chromosome 9. It contains 7 exons 
which after transcription, give messenger RNA (mRNA) with a coding sequence 1293 bp 
long. Allelic variants have only been recently identified in zebrafish pxr, where 3 non-
synonymous SNPs have been located in the hinge region and LBD (Figure 1.5; Bainy et al., 
2013). The effect of these variants on zebrafish Pxr (zfPXR) activation and cyp3a65 
expression is currently unknown, but Pxr from different strains of zebrafish has been contain 
to possess differing levels of ligand activation (Lille-Langøy, unpublished data). 
 
 
Figure 1.5. The modular structure of the coding region of zebrafish Pxr including the LBD, DBD 
and AF-2. The location of the three known non-synonymous SNPs and their associated amino 
substitutions are indicated by the grey arrow heads. Figure adapted from Bainy et al. (2013). 
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1.5 Zebrafish 
Zebrafish (Danio rerio) are small freshwater fish which belong to the minnow family 
(Cyprinidae) (Figure 1.6). They are distributed throughout the Himalayas, but are kept in 
captivity as research animals across the world. Adults generally grow up to 4 cm in length 
under captivity, but individuals can grow as large as 6 cm. They thrive in tropical 
environments and can live up to 5 years, but usually live only between 2 and 3 years in 
captivity. Zebrafish are omnivorous and their diet consists of both phytoplankton and 
zooplankton (Spence et al., 2008). Different strains have been classified for zebrafish, and 
these are maintained by the Zebrafish Model Organism Database (ZFIN) (Sprague et al., 
2006). Presently there are a total of 29 wild-type lines listed on the ZFIN database, including 
strains such as Tupfel long fin (TL), Tübingen (Tu), Singapore Wild-type (SWT) and 
AB/Tübingen (AB/Tu). 
 
 
Figure 1.6. A zebrafish adult, approximately 2 years old. Photo by Daniel Hitchcock. 
 
 
1.5.1 Zebrafish as a model organism 
Zebrafish are notable for their fast generation time, where individuals can begin reproduction 
within 3 to 4 months. Embryos develop very quickly and fertilisation success can be seen by 
eye, whereby eggs become transparent. Females can lay up to a hundred eggs per mating and 
spawn a few times per week (Spence et al., 2008).  Their quick developmental period and 
ability to lay many eggs make zebrafish useful for research, since embryos can be acquired 
quickly and in large numbers. 
 
In 2013 the zebrafish genome was sequenced, allowing researchers to determine similarities 
between humans and zebrafish (Howe et al., 2013). Their early developmental period and 
response to human drugs has also been well-studied, making them a useful model species in 
toxicology and biomedicine (Kimmel, 1989; Aleström et al., 2006). Zebrafish have also been 
shown to respond to compounds in a similar manner as mammals and humans in toxicity 
testing, meaning that embryos and adults serve as ideal models (Guyon et al., 2007; Driessen 
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et al., 2013). In fact, teratology assay models are commonly used in zebrafish embryos for 
drug discovery and screening (Rubinstein, 2003; Rubinstein, 2006). 
 
The use of zebrafish as a model organism in toxicology makes them a valuable species for 
research and drug development (Barros et al., 2008). For this reason, embryos serve as a 
good starting point for compound exposure, nuclear receptor activation and target gene 
induction. 
 
1.5.2 Effects of clotrimazole on zebrafish 
Clotrimazole (CAS number: 23593-75-1) is found in topical creams, is used to treat fungal 
infections and is listed on the World Health Organisation’s list of essential medicines (Figure 
1.7) (World Health Organization, 2013). However, this compound is also a pollutant since it 
is discharged into the aquatic environment and known to affect aquatic organisms (OSPAR 
Commission, 2013). In zebrafish, it has been reported that the compound’s effective 
concentration for 20% of the exposed fish (EC20) is 0.84 µM. At this concentration, affected 
fish exhibited “abnormal swimming behaviour”, which is probably defined as any deviation 
from their normal upright position (Barros et al., 2008). Clotrimazole is known to be a strong 
activator of Pxr and inducer of the transcription of cyp3a65 (Bresolin et al., 2005) and is 
known to act as an EDC to some extent, by altering levels of hormones involved in 
steroidogenesis (Baudiffier et al., 2012). 
 
 
Figure 1.7. Chemical structure of clotrimazole. 
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1.6 Antibodies 
Antibodies are Y-shaped proteins produced by the immune system that tag antigens for 
neutralisation (Figure 1.8). Immunoglobulin G (IgG) is the most commonly occurring isotype  
 
Figure 1.8. Structure of an antibody, including the symmetrical heavy (blue) and light (purple) 
chains linked to one another by cysteine disulphide bonds. The variable regions of the coupled light 
and heavy chain represent the paratope, the antigen binding site. 
 
 
in serum (Murphy, 2012). IgG weighs approximately 150 kD and contains two identical 
heavy chains (approximately 50 kD) and two identical light chains (approximately 25 kD) 
(reviewed in Lipman et al., 2005). For IgG, the two heavy chains are bound to one another by 
disulphide bonds and each of these is bound to a single light chain, with the number and 
specific location of disulphide bonds varying according to subclass (Liu and May, 2012). 
Each chain contains a constant and a variable region, and the combination of the light and 
heavy chain’s variable region represents an antibody’s paratope. The most important 
component of IgG that allows it to bind to antigens is the Fab (Fragment, antigen-binding) 
region, which constitutes the two arms of the Y, on which the variable regions containing the 
paratopes are called the complementarity determining regions (CDRs) (Murphy, 2012). The 
Fc (Fragment crystallisable) region represents the tail of the Y. 
 
1.6.1 Antibody and antigen interaction 
Antibodies are produced by the adaptive immune system after the body has been exposed to 
an antigen, either from within the body or a foreign source (Murphy, 2012). Antigens can be 
cells, microparticles or even proteins. Antibodies are mostly specific to a single antigen and 
bind to its epitope: a segment of the antigen to which the immune system has responded 
 11 
 
(Abbas et al., 2012). Interaction between an antibody and epitope depends on both the 
structure of an antibody’s CDR and the epitope. For example, if the interaction between an 
antibody’s CDR and epitope is strong and specific, then the antibody is monoreactive, i.e. it 
only binds to a single antigen. Polyreactive antibodies also exist, which are non-specific and 
capable of binding to different antigens (Notkins, 2004). The structure of the epitope is also 
important, since conformational epitopes are mostly only recognised by their tertiary 
structure, whereas linear epitopes are usually only recognised by their primary structure 
(Murphy, 2012). 
 
1.6.2 Production of antibodies: immune response 
Antibodies are an extremely useful tool in research, since they can be used to detect the 
presence of an antigen within a biological sample by binding to its epitope. For example, 
antibodies are a key tool in immunoreactive detection, e.g. in immunochemical detection of 
proteins, enzyme-linked immunosorbent assay (ELISA) and immunohistochemistry (see 
Methods 3.4.4). 
 
Antibodies specific to antigens are often obtained from immunisation (Figure 1.9) (Murphy, 
2012). This involves administering an antigen to an individual (primary exposure), usually by 
vaccine, causing the adaptive immune system to produce antibodies specific to that antigen 
(primary response). The primary response involves the differentiation of naïve B cells into 
antibody-producing effector B cells, which respond to the foreign antigen. Some naïve B 
cells also differentiate into long-lived, clonal memory B cells, which are capable of 
differentiating into effector B cells upon secondary exposure to the same antigen. For this 
reason, a secondary response to the same antigen will elicit a much stronger response than a 
primary exposure. The concept behind immunisation is used to acquire antibodies specific to 
desired antigens. 
 
1.6.3 Monoclonal and polyclonal antibodies 
Antibodies can be obtained from individuals in a number of ways. Depending on the method 
used, antibodies can vary in their specificity, being either monoclonal or polyclonal in nature. 
Polyclonal antibodies bind to multiple epitopes of a single antigen. They are obtained from 
the antiserum of blood of an immunised animal, and cross-reactive species can be removed 
using affinity purification (Robinson et al., 1988). Polyclonal antibodies, including 
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commercial antibodies, are cheap and quick to obtain, but their cross-reactivity to multiple 
epitopes often makes them less sensitive (Lipman et al., 2005). 
 
 
Figure 1.9. A representation of antigen exposure. During the primary exposure, naïve B cells (blue) 
differentiate both into effector B cells (purple) and memory B cells (green). Low-affinity IgM 
antibodies are produced by the effector B cells and are responsible for the majority of the primary 
response. Long-lived clonal memory B cells also remain in the body after the primary response. A 
secondary exposure to the same antigen elicits a faster and greater production of specific IgG 
antibodies due to the presence of memory B cells. 
 
 
On the other hand, monoclonal antibodies bind only to a single epitope of a single antigen. 
They are highly specific, but can only be obtained by extracting B cells from an animal, 
making them more difficult and time-consuming to obtain. However, since monoclonal 
antibodies originate from a single clonal cell, antibodies obtained in this manner will always 
have the same affinity against the same epitope (Lipman et al., 2005). 
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1.6.4 Hybridoma technology 
Hybridoma technology, one method to obtain monoclonal antibodies, was first described by 
Köhler and Milstein (1975) (Figure 1.10). The process involves the immunisation of a mouse 
against a desired antigen, isolation of effector B cells from the spleen, and fusion of these 
cells with myeloma cells (immortal, cancerous effector B cells which have been modified to 
not secrete antibodies) (reviewed in Chiarella and Fazio, 2008). The fused cell is referred to 
as a hybridoma, and with limiting dilution, one can obtain single clonal cells which can be 
tailored to secrete antibodies indefinitely. Antibodies are collected in the supernatant and 
these are screened against the original antigen in order to determine correct specificity. In 
2011, in a previous Master’s project, hybridoma cell lines produced from spleen cells of mice 
immunised by either hPXR or zfPXR were developed (Davies, 2011). 
 
 
Figure 1.10. Production of hybridoma cells secreting monoclonal antibodies after immunisation of 
mice with a desired antigen. Adapated from Joyce and ter Meulen (2010). 
 
 
1.6.5 Antibodies and PXR 
Antibodies have been used to expand our understanding of PXR activity in cells. For example, 
monoclonal mouse antibodies have been used to determine the subcellular location of human 
PXR in breast cancer carcinomas (Miki et al., 2006). In mice, polyclonal goat antibodies have 
been used to determine that PXR predominantly exists in the cytoplasm before ligand 
treatment and in the nuclei after exposure to pregnenolone carbonitrile (PCN) (Kawana et al., 
2003). The development of polyclonal rabbit antibodies has been used to demonstrate that 
PXR can be obtained and purified from a prokaryotic cell line by cloning the gene of the 
antigen into an expression vector (Saradhi et al., 2005). 
 
Another powerful tool which utilises antibodies is Chromatin immunoprecipitation (ChIP). 
ChIP is a tool that has been developed to determine which DNA binding sites are associated 
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with transcription factors (Orlando, 2000). This involves the binding of a desired 
transcription factor with chromatin, shearing of genomic DNA into fragments (300–500 bp), 
and purification of the DNA fragments for sequencing. So far, ChIP has only been carried out 
on mouse PXR (Cui et al., 2010) and obtaining antibodies specific to PXR of other species 
could be used to further our understanding of PXR function. 
 
1.7 Aims 
Genetic variants of human PXR have been identified and now studies are focusing on how 
this variation might affect transcriptional variation of its target genes. However, the zebrafish 
pxr gene has received little attention, despite the species’ and gene’s importance and 
relevance in toxicology and biomedicine. In addition, the use of zebrafish embryos could 
prove to be a cheaper, easier and faster way of collecting data in this field of research. One of 
the main goals in this study is to develop a method for sequencing pxr from individual 
zebrafish embryos, and to compare these sequences with recently identified allelic variants. 
 
Antibodies are of great importance in molecular biology and the establishment of hybridoma 
cell lines producing monoclonal antibodies specific to human and zebrafish PXRs can lead to 
many new and exciting possibilities. However, there is currently no commercial antibody 
available with specificity against zebrafish Pxr. Therefore, another main goal in this study is 
to evaluate the specificity of monoclonal antibodies, previously developed in this laboratory, 
against PXR orthologs. 
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2. Materials 
 
2.1 General chemicals 
Chemical name Formula Supplier / catalogue / product 
number 
30% Acrylamide : Bis-acrylamide solution, 
37.5:1 
 Sigma Aldrich / A3699 
Ammonium persulphate (APS) (NH4)2S2O8 Sigma Aldrich / A9164 
Betaine solution  Sigma Aldrich / B0300 
Chloroform CH3Cl Sigma Aldrich / 34854 
Clotrimazole C22H17CIN2 Sigma Aldrich / C6019  
Coomassie brilliant blue G-250 (CBB G-
250) 
C47H48NaO7S2 Merck / 1.15444 
Coomassie brilliant blue R-250 (CBB R-
250) 
C45H44N3O7S2Na Sigma Aldrich / B0149 
Diethylpyrocarbonate (DEPC) C6H10O5 Sigma Aldrich / D5758 
Dimethyl suphoxide (DMSO) C2H6OS Sigma Aldrich / D2650 
Disodium hydrogen phosphate 
monohydrate 
Na2HPO4•H2O Merck / 1.06346 
Dithiothreitol (DDT) C4H10O2S2 Sigma Aldrich / 43817 
Ethanol (EtOH) C2H5OH Sigma Aldrich / 32221 
Ethidium bromide (EtBr) C21H20BrN3 Sigma Aldrich / E1510 
Ethylenediaminetetraacetic acid (EDTA) C10H16N2O8 Merck / 324503 
Formamide CH3NO Sigma Aldrich / F9037 
Glacial acetic acid CH3COOH Merck / 1.00063 
Glycerol 85% C3H8O3 Merck / 1.04094 
Glycine C2H5NO2 Sigma Aldrich / G8898 
HEPES C8H18N2O4S Sigma Aldrich / H3375 
Hydrochloric acid HCl Sigma Aldrich / 339253 
Isopropyl β-D-1-thiogalactopyranoside 
(IPTG) 
C9H18O5S Sigma Aldrich / I6758 
Isoamylalcohol C5H12O Merck / 1.00979 
Isopropanol C3H8O Kemetyl / 200-661-7 
L-glutamine C5H10N2O3 Sigma Aldrich / G7513 
Magnesium chloride hexahydrate MgCl2•6H2O Sigma Aldrich / M9272 
Methanol CH3OH Sigma Aldrich / 32212N 
N,N,N',N'-tetramethyl-ethylenediamine 
(TEMED) 
C6H16N2 Sigma Aldrich / T9281 
Ortho phosphoric acid 85% H3PO4 Merck / 1.00573 
Potassium chloride KCl Sigma Aldrich / P9541 
Potassium phosphate dibasic trihydrate K2HPO4•3H2O Sigma Aldrich / P5504 
Rifampicin C43H58N4O12 Sigma Aldrich / R3501 
Sodium chloride NaCl Merck / 1.06404 
Sodium dihydrogen phosphohate dihydrate NaH2PO4•2H2O Merck / 1.06346 
Sodium dodecyl sulphate (SDS) (20% w/v) NaC12H25SO4 Bio-Rad / 161-0418 
Sodium pyruvate C3H3NaO3 HyClone / SH30231.01 
Tris base (Trizma
®
 base) C4H11NO3 Sigma Aldrich / T1503 
β-mercaptoethanol C2H6OS Sigma Aldrich / M7154 
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2.2 General solutions, compounds, media and supplements 
Chemical name Formula Supplier / catalogue / 
product number 
0.25% trypsin-EDTA  Sigma Aldrich / T4049 
0.5 M Tris-HCl buffer pH 6.8 (HOCH2)CNH2•HCl Bio-Rad / 161-0799 
1.5 M Tris-HCl buffer pH 8.8 (HOCH2)CNH2•HCl Bio-Rad / 161-0798 
Albumin from bovine serum  Sigma Aldrich / A4503 
Ampicillin sodium salt C16H18N3NaO4S Sigma Aldrich / A9518 
Dulbecco’s Modified Eagle Medium (DMEM)  Sigma Aldrich / D5671 
Fetal Bovine Serum (FBS)  Sigma Aldrich / F9665 
Kanamycin C18H36N4O11 Sigma Aldrich / K1876 
Non-fat dried milk  Normilk AS 
Opti-MEM
®
 I (1×)  Gibco / 11058-021 
Pencillin Streptomycin (Penstrep)  Gibco / 15140 
SeaKem
®
 LE Agarose  Lonza / 50004 
Trypan bluestain C34H28N6O14S4 Cambrex / 17-492E 
Tryptone (peptone from casein)  Merck / 1.11931 
Yeast extract  Sigma Aldrich / 70161 
QIAzol
® 
Lysis Reagent  Qiagen 
Lysozyme  Sigma 
EDTA-free protease inhibitor × 100  Roche 
cOmplete ULTRA Tablets, Mini, EDTA-free, 
EASYpack 
 Roche / 05 892791 001 
5 × Boiling buffer   
TRI Reagent
®
  Sigma Aldrich / T9424 
RNase-free water  Qiagen 
 
 
2.3 Kits 
Name Description Supplier / catalogue / lot 
number 
Amersham™ ECL™ Prime 
Western Blotting Detection 
Reagent 
Western blot chemiluminescence 
kit 
GE Healthcare / RPN2232 / 
9466590 
TransIT
®
-COS Transfection Kit Plasmid transfection kit into COS-7 
cells 
Mirus / MIR2190 / 
KLN6065 
NucleoBond
®
 Xtra Midi 
plasmid DNA repurification kit 
Plasmid repurification of 
transformed E. coli cells 
Marcherey-Nagel / 
740410.50 / 1201/ 001 
SuperSignal
®
 West Pico 
Chemilumiscent Substrate 
Western blot chemiluminescence 
kit 
Thermo Scientific / 34080 
Phase Lock Gel Heavy 1.5 mL Gel separating RNA and DNA 
fractions during extraction 
5 Prime / 2302810 
RNA
®
 MinElute
TM 
Cleanup Kit RNA clean up kit after phase 
separation 
Qiagen / 74204 
Protein G HP SpinTrap
TM
 Purification of hybridoma 
supernatant 
GE Healthcare / 28-9031-34 
qScript
TM
 cDNA Synthesis Kit cDNA synthesis kit from RNA Quanta Biosciences / 95047 
GenElute
TM
 PCR Clean-Up Kit  Cleanup of PCR product after 
amplification 
Sigma-Aldrich / NA1020 
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2.4 Prokaryotic cell lines 
Name Description Supplier 
StrataClone™ SoloPack 
competent cells 
Cells used for the heatshock transformation 
of plasmids containing PXR orthologs 
Stratagene 
E. coli Rosetta pET30b spotty 
FL zfPXR 
Cells containing a pET30b plasmid 
encoding a 6×his-tagged full-length zfPXR 
Roger Lille-Langøy 
E. coli Rosetta  Non-transformed cells Roger Lille-Langøy 
 
 
2.5 Eukaryotic cell lines 
Name Description Reference 
COS-7 African green monkey cell line: CV-1 (simian) in 
Origin containing SV40 genetic material, line 7. 
Used to express PXR 
Jensen et al. (1964); 
Gluzman (1981) 
 
 
2.6 Plasmids 
Name Description Supplier 
pSG5 FL hPXR Plasmid containing full length hPXR Roger Lille-Langøy 
pcDNA FL zfPXR Plasmid containing full length zfPXR Roger Lille-Langøy 
pET30b His-tagged FL 
zfPXR 
Plasmid containing fused His-tag and full 
length zfPXR 
Roger Lille-Langøy 
 
 
2.7 Hybridoma supernatants 
Designation Produced in Isotype Specificity Supplier 
5E4F9D9 Mouse IgG hPXR Richard Davies, 2011 
9F10D4B2 Mouse IgG hPXR Richard Davies, 2011 
12D5F6E6 Mouse IgG hPXR Richard Davies, 2011 
5E4B11D6 Mouse IgG hPXR Richard Davies, 2011 
8E2B8D7 Mouse IgG hPXR Richard Davies, 2011 
9E11D2C4 Mouse IgG zfPXR Richard Davies, 2011 
8F11C8C9 Mouse IgG zfPXR Richard Davies, 2011 
9E11C8D10 Mouse IgG zfPXR Richard Davies, 2011 
 
 
2.8 Molecular weight and size standards 
Name Description Supplier / catalogue 
number 
2-Log DNA Ladder Concentration 50 ng / µL; range 0.1–10 kb. 
Dissolved in 5 mM TrisHCl and 1 mM EDTA. 
Used for agarose gel electrophoresis 
New England Biolabs 
/ N3200L 
Precision Plus Protein™ 
Standards All Blue 
Ten blue-stained proteins; range 10–250 kD. 
Used for SDS-PAGE. 
Bio-Rad / 161-0373 
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2.9 Enzymes for amplification and sequencing 
Name Description Supplier / product number 
PrimeSTAR
®
 GXL DNA 
Polymerase 
Used for the PCR amplification of β-
actin and zfPXR primers. 
TaKaRa / R050A 
BigDye
®
 Terminator v3.1 Used for the PCR amplification of 
zfPXR primers for sequencing. 
Applied Biosystems / 
4337455 
 
 
2.10 Primers 
Name Description Sequence (5'–3') Supplier 
zf_actinF/811 Primer to determine 
successful synthesis of 
RNA to cDNA 
GAGAAGATCTGGCATCACACC Sigma 
zf_actinR/812 Primer to determine 
successful synthesis of 
RNA to cDNA 
GGTCTCGTGGATACCGCAAGA Sigma 
zfPXR(1)Ncol-F Primer for the 
amplification of 
zfPXR from AA1 
GTCACCATGGCAATGTCCCGCT
TATATGAC 
Sigma Aldrich 
zfPXR-BamHI-R Primer for the 
amplification of 
zfPXR from AA430 
TTGTGGATCCGAGGACCTAGGT
GTCTTTGC 
Sigma Aldrich 
zfPXR_seq_478_
Fwd 
Primer for the 
sequencing of zfPXR  
TTCGACATGACTTGTGCCCA Sigma Aldrich 
zfPXR_seq_1070
_Rev 
Primer for the 
sequencing of zfPXR 
TTGTGGTCTGTCACACCAGG Sigma Aldrich 
 
 
2.11 Commercial antibodies 
Antibody Produced 
in 
Isotype Reactivity Supplier Product number 
Anti-human PXR  Mouse IgG2A Monoclonal Perseus Proteomics PP-H4417-00 
Anti-mouse IgG, 
HRP Conjugate 
Goat IgG Polyclonal Dako P0447 
Anti-mouse IgG 
(H+L), HRP 
Conjugate 
Goat IgG Monoclonal Molecular Probes 
Invitrogen™ / Life 
Technologies 
G-21040 
Anti-His, clone 
2B5 
Mouse IgG1 Monoclonal OriGene TA150088 
 
 
2.12 Consumables 
Name Supplier Product number 
Immobilon
®
-P Transfer 
Membrane (pore size 0.45 µm) 
Millipore
TM
 IPVH00010 
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2.13 Instrumentation 
Category Name Manufacturer 
Blotting Trans-Blot
®
 SD Semi-dry Transfer cell Bio-Rad 
Cell density Ultraspec 10 Amersham Biosciences 
Centrifugation CT15RE Himac VRW 
 Galaxy ministar VRW 
 Heraeus Multifuge X3R Thermo Scientific 
 Avanti J-26 XP Bekman Coulter 
Electrophoresis PowerPac HC Bio-Rad 
Heating Thermomixer compact Eppendorf 
 GD100 Grant 
Homogenisation XENOX motorised hand tool XENOX 
 Stainless steel pestle, cone diameter 8 mm Carl-Roth 
Imaging Gel Doc™ EZ Imager Bio-Rad 
 ChemiDoc™ XRS+ Bio-Rad 
Incubation Galaxy 170 R New Brunswick 
 Infors HT Multitron Standard VRW 
  Termaks 
 INCU-Line VRW 
Microscopy DMIL LDE CMS GmbH LEICA Microsystems 
 SMZ-645 Nikon 
Mixing  VWR International 
 Rotator SB3 Stuart
®
 
 HS 501 digital IKA
®
-WERKE 
pH measurement pHM210 Standard pH Meter MeterLab
®
 
Plate reading EnSpire
®
 Multimode Plate Reader PerkinElmer 
Sequencing 3730XL DNA Sequencer Applied Biosystems 
Spectrophotometry ND-1000 NanoDrop
®
 
Sonication 4710 Series Ultrasonic Homogenizer Cole-Pharmer Instrument Co. 
Thermocycling DOPPIO VWR 
Water supply Advantage A10 Millipore 
Weighing S1-64 Denver Instrument 
 EK-300i AND 
 
 
2.14 Water quality 
MΩcm@25°C: 18.2 
Ppb TOC: 5 
 
Deionised type 1 ultrapure water, Milli-Q 
 
 
2.15 Solutions, buffers and media 
Heatshock transformation 
Super optimal broth (SOB) medium 
2% Tryptone (w/v) 
0.5% Yeast extract (w/v) 
10 mM NaCl 
2.5 mM KCl 
Super optimal broth with catabolite repression 
(SOC) medium 
1 × SOB 
5 mM MgCl2 
5 mM MgSO4 
20 mM Glucose 
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Bacterial growth 
1× Lysogeny broth (LB) medium 
1% Tryptone (w/v) 
1% NaCl (w/v) 
0.5% Yeast extract (w/v) 
 
COS-7 maintenance 
Dulbecco’s modified Eagle medium (DMEM)++ medium 
1 mM Sodium pyruvate 
4 mM L-glutamate 
100 U / mL Penstrep 
10% mL Fetal Bovine Serum (FBS) (v/v) 
-> add to 500 mL DMEM 
 
Agarose gel electrophoresis (AGE) 
5 × TBE 
0.5 M Tris 
0.5 M Boric acid 
10 mM EDTA pH 8.0 
 
0.7% Agarose gel in TBE 
0.7% Agarose (w/v) 
0.5 × TBE 
1 × TAE 
40 mM Tris 
40 mM Acetic acid 
1 mM EDTA pH 8.0 
 
1% Agarose gel in TAE 
1% Agarose (w/v) 
1 × TAE 
 
× 10 loading buffer 
1% SDS 
50% Glycerol 
0.05% Bromophenol blue 
 
Cytoplasmic and nuclear extraction 
Buffer A 
200 mM HEPES pH 7.9 
100 mM KCl 
10 mM MgCl2•6H2O 
10 mM DTT 
-> Add 1 × protease inhibitor before use 
Buffer C 
200 mM HEPES pH 7.9 
10 mM MgCl2•6H2O 
20% Glycerol 
420 mM NaCl 
10 mM EDTA 
-> Add 1 × protease inhibitor before use 
Bradford assay 
Bradford Reagent 
1 : 1 of A : B 
A:  17% Phosphoric acid (v/v) 
B:  0.08% Coomassie Brilliant Blue (CBB) G-250 (w/v) 
 10% EtOH (v/v) 
 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis(SDS-PAGE) 
12.5% resolving gel (all amounts v/v) 
29.8% deionised H2O 
25% 1.5 M Tris-HCl pH 8.8 
1% 10% SDS 
42% mL Acrylamide : Bis solution 37.5 : 1 
2% 10% APS 
0.2% µL TEMED 
 
 
 
4% stacking gel (all amounts v/v) 
59.1% deionised H2O 
25% mL 0.5 M Tris-HCl pH 6.8 
1% µL 10% SDS 
12.5% µL Acrylamide : bis solution 37.5 : 1 
2% µL 10% APS 
0.4% µL TEMED 
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10% resolving gel (all amounts v/v) 
39% deionised H2O 
25% 1.5 M Tris-HCl pH 8.8 
1% 10% SDS 
33% mL Acrylamide : Bis solution 37.5 : 1 
2% 10% APS 
0.2% µL TEMED 
10 × TGS pH 8.3 
250 mM Tris 
1920 mM Glycine 
1% SDS 
 
 
 
Coomassie staining 
Coomassie staining agent 
2 g / L CBB R-250 (w/v) 
40% EtOH (v/v) 
10% Acetic acid (v/v) 
Coomassie destaining agent 
40% EtOH 
10% Acetic acid 
 
Western blot buffers 
10 × Pre-Semi-Dry Transfer Buffer 
180 mM Tris 
390 mM Glycine 
 
1 × Semi-Dry Transfer Buffer 
1 × Pre-Semi-Dry Transfer Buffer 
20% MeOH 
10 × Pre-Wet Transfer Buffer 
250 mM Tris base 
1920 mM glycine 
 
1 × Wet Transfer Buffer 
1 × Pre-Wet Transfer Buffer 
20% MeOH 
 
Phosphate buffered saline (PBS) buffers 
10 × PBS 
1370 mM NaCl 
27 mM KCl 
104 mM Na2HPO4•2H2O 
11 mM K2HPO4•3H2O 
1 × PBS 5% milk 
1 × PBS 
5 % Dry milk (w/v) 
 
1 × PBS-Tween (PBS-T) 
1 × PBS 
0.05% Tween-20 
 
Tris buffered saline (TBS)  buffers 
10 × TBS pH 7.6 
200 mM Tris base 
1370 mM NaCl 
1 × TBS 5% milk 
1 × TBS pH 7.6 
5 % Dry milk (w/v) 
1 × TBS-T 
1 × TBS pH 7.6 
0.05% Tween-20 
 
Antibody purification 
BINding buffer pH 7.0 
20 mM Sodium phosphate 
From:  8.9 mL 20 mM NaH2PO4•H2O in 50 mL deionised H2O 
 11.1 mL 20 mM Na2HPO4•2H2O in 50 mL deionised H2O 
 
NEUtralising buffer pH 9.0 
1 M Tris 
 
ELUtion buffer pH 2.7 
0.1 M Glycine 
Prokaryotic protein extraction 
1 × PBS salt buffer 
300 mM NaCl 
 
Zebrafish media 
60 × E3 medium 
300 mM NaCl 
100 mM KCl 
20 mM CaCl2 
20 mM MgSO4 
0.1% methylene blue 
E3 control medium (adults) 
1 × E3 
0.25% DMSO 
E3 control medium (embryos) 
1 × E3 
1% DMSO 
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E3 treatment medium (adults) 
1 × E3 
1 µM clotrimazole 
0.25% DMSO 
E3 treatment medium (embryos) 
1 × E3 
1 µM clotrimazole 
1% DMSO 
 
Ribonuclease (RNase)-free solutions 
Diethylpyrocarbonate (DEPC)-treated water 
0.1% DEPC 
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3. Methods 
 
3.1 Experimental overview 
A strategy for screening hybridoma supernatants against PXR orthologs and identification of 
allelic variants in zebrafish was carried out according to Figures 3.1 and 3.2. 
 
 
Figure 3.1. Strategy for the evaluation of hybridoma supernatant immunoreactivity. Details for each 
step are given in Sections 3.2 to 3.6.  
 
 
Figure 3.2. Strategy for identification of zebrafish pxr variants. Details for each step are given in 
Sections 3.7 to 3.9. 
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3.2 Plasmid purification 
In order to produce PXR orthologs of high quality, PXR was previously cloned from both 
human and zebrafish and ligated into plasmids. This work was carried out by Roger Lille-
Langøy at the University of Bergen. Repurification of these plasmids was necessary in order 
to carry out transfection into a eukaryotic cell line. 
 
3.2.1 Heatshock transformation 
Heatshock transformation is a technique that is used to genetically alter bacterium by 
introducing exogenous genetic material. Momentarily increasing the temperature of the cells 
induces the incorporation of exogenous DNA, e.g. plasmid DNA (pDNA). The mechanism 
behind this process is not fully understood, but it is known that topology of the plasmids is 
important when maximising transfer efficiency (Kreiss et al., 1999). 
 
StrataClone SoloPack competent cells were used to produce the pSG5 hPXR and pcDNA 
zfPXR plasmids. These plasmids contain recombinant genes including full length human 
PXR and zebrafish pxr respectively (Figure 3.3). Purified plasmids and cells were brought 
together by adding 20 ng of each plasmid to 25 µL of thawing competent bacterial cells 
(stored at –80 ºC) and incubating on ice for 20 minutes. Uptake of pDNA was facilitated by 
heatshocking the cells at 42 ºC in a water bath for 45 seconds then immediately cooling on 
ice for 2 minutes. 125 µL of SOC media (preheated to 42 ºC) was added to the heatshocked 
cells were added to and incubated at 250 rpm for 1 hour at 37 ºC to allow for the expression 
of the antibiotic resistance gene (AmpR/β-lactamase). Successfully transformed cells were 
selected for by cultivation on LB-agar with 100 μg/mL ampicillin. Two different volumes of 
the transformation reactions (100 µL and 10 µL) were inoculated to LB-agar plates and 
incubated for at 37 ºC overnight. 
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Figure 3.3. Maps of plasmids used in the eukaryotic expression of antigen. Plasmid 
pcDNA FL zfPXR (A) and pSG5 FL hPXR (B) were used in the transient transfection of COS-7 cells. 
PCMV and PR correspond to the promoter regions of each plasmid and ampicillin corresponds to the 
antibiotic resistance gene. 
 
 
3.2.2 High quality plasmid preparation by medium scale purification of plasmid DNA  
Plasmids can be purified through a column containing silica resin which binds to the 
phosphate backbone of DNA under acidic conditions (Bimboim and Doly, 1979). The 
application of a high salt elution buffer can shift the pH to alkaline conditions, allowing for 
the disassociation and collection of purified pDNA after centrifugation and wash steps. 
Single bacterial colonies containing either the pSG5 hPXR or pcDNA zfPXR plasmid were 
then cultured for plasmid purification. An inoculation loop was used to scrape a single colony 
from the LB-agar plate to inoculate a 100 mL LB culture containing 100 µg/L of ampicillin. 
The culture was then incubated at 37 ºC at 250 rpm overnight. Because both plasmids 
contained genes resistant to ampicillin, only bacterial cells containing the plasmid could 
successfully replicate. 
 
The NucleoBond
®
 Xtra Midi plasmid DNA purification kit (Marcherey-Nagel) was used to 
extract the plasmids from the transformed bacteria cells. In the final step, 0.5 mL of deionised 
water (Type 1 ultrapure water, Milli-Q) was used to redissolve the precipitated pDNA pellet. 
The tube containing DNA pellet was shaken at 4 ºC overnight to ensure complete recovery of 
the pDNA. Dissolved pDNA was collected by centrifugation at 10000 × g for 1 minute at 4 
ºC, giving the final purified plasmid product. 
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3.2.3 Quantification and evaluation of plasmid DNA by spectrophotometry 
Plasmids were diluted to 1:20 in deionised water and the absorbance of each sample (1–2 µL) 
was measured at 260 nm in a NanoDrop
®
 ND 1000 spectrophotometer. The concentration of 
plasmids was determined assuming that an absorbance of 1.0 at 260 nm corresponds to 50 
µg/mL of DNA. The ratio between the absorbance of DNA (at 260 nm) and contaminants 
including proteins (at 280 nm) was also verified (Sambrook and Russell, 2001). An A260/280 
ratio greater than 1.8 suggests a high purity of DNA; however the usefulness of this ratio as a 
quality measurement is often debated (see Discussion 5.2.3). 
 
3.2.4 Visualisation of nucleic acids by agarose gel electrophoresis  
Plasmid quality was assessed using agarose gel electrophoresis (AGE). This method separates 
charged molecules in a gel matrix according to their length when subjected to an electric field. 
Linear nucleic acids contain an even distribution of negatively charged phosphates along their 
backbone, meaning that their migration through a gel depends on molecular size alone. A 
staining agent such as ethidium bromide (EtBr) is also added to the gel since EtBr binds to 
nucleic acids and fluoresces when exposed to ultraviolet (UV) light. 
 
Double stranded pDNA however is circular and do not travel through a gel matrix in a linear 
fashion. This means that the size of pDNA cannot be determined by migration distance. 
Circular plasmids are capable of winding into coils, and high quality plasmids are often 
attributed as being supercoiled in topology. AGE can be used to determine plasmid quality 
since supercoiled plasmids are more compressed and travel further through a gel matrix than 
uncoiled plasmids, despite having the same molecular weight (Aaij and Borst, 1972). 
 
200 ng of each plasmid and 2-log DNA ladder were loaded onto gels containing 0.7% 
agarose in 0.5 × TBE buffer and 50 µg/mL of EtBr. The size of gel matrices were either 7 × 5 
cm or 7 × 10 cm depending on the number of samples loaded. Gels were run at 110 V in 0.5 
× TBE buffer for 35 minutes. Nucleic acids were visualised under UV light using a Gel 
Doc™ EZ Imager and ImageReady software (v3.0). 
 
3.3 Eukaryotic protein expression for antigen production 
In order to test the immunoreactivity of PXR against hybridoma supernatants, a eukaryotic  
cell line was cultured and transfected with recombinant pDNA to produce either an hPXR or  
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zfPXR antigen. The COS-7 cell line was chosen because it is a continuous cell line which is 
easy to maintain, grows at a very rapid rate and is commonly used for recombinant protein 
expression. In addition, COS-7 cells have already been established in our laboratory as a 
model for the transient expression of proteins. 
 
3.3.1 Preparation and maintenance of COS-7 cell lines 
COS-7 cells stored in liquid nitrogen were thawed with pre-warmed DMEM++ media 
(Materials 2.15). The cells were pelleted by centrifugation (500 × g for 5 minutes) and the 
supernatant was carefully removed by pipetting. The pellet was resuspended in 10 mL of 
DMEM++ media, and this mixture containing the COS-7 cells was added to a 10 cm culture 
plate and incubated at 37 ºC with 5% CO2. The COS-7 cells formed as a monolayer on the 
bottom of the plate. 
 
Confluence was checked daily under a microscope and media was replaced every second to 
third day. Whenever confluence exceeded 70%, the cultures were split by trypsinisation. This 
involved the disassociation of COS-7 cells from the plate and the reseeding of these into 
subcultures (i.e. splitting). During splitting, DMEM++ media was removed and 10 mL of 
sterile PBS was added to remove any dead or unattached cells and serum-containing media 
which might inhibit trypsinisation. PBS was removed and 2 mL of 0.05 % trypsin-EDTA was 
added to disassociate the COS-7 cells the culture plate. Culture plates were incubated for 30 
seconds at room temperature before excess trypsin was removed. The culture was then 
incubated for 5 minutes at 37 ºC with 5% CO2. COS-7 cells were then resuspended with 10 
mL of pre-warmed DMEM++ media to obtain a single cell suspension. Cells were reseeded 
to new culture plates in a dilution of 1:5 and maintained as described above. 
 
3.3.2 Determining cell density using a haemocytometer 
Cells in each culture plate were trypsinated as described above and resuspended using 5 mL 
of DMEM++ media. The resuspended cells were pooled and 25 µL of this culture was stained 
with 25 µL of tryphan blue. Stained cells were counted using a haemocytometer, a device 
which can determine cell concentration given the volume of the counting chambers is known. 
 
3.3.3 Transient transfection of COS-7 cells 
Transfection is a technique that is used to genetically alter eukaryotic cells by introducing 
exogenous genetic material, e.g. pDNA. Transfection of plasmids is more successful when 
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circular DNA is predominantly supercoiled and highly pure. The mechanism behind this 
process is not fully understood, but it is known that supercoiled plasmids are more readily 
taken up by cells than uncoiled plasmids (Kreiss et al., 1999). Transfected cells express a 
recombinant protein, which can then be used for further studies. In our case, we wanted to 
use the transfected protein as an antigen for antibody analyses. 
 
Fifteen culture plates containing COS-7 cells were cultured until each plate became 
approximately 70-80% confluent, and reseeded to twelve new culture plates at a 
concentration of 24.6 × 10
5
 cells/plate the day prior to transfection (Table 3.1). Reseeded 
plates were adjusted to a volume of 10 mL using DMEM++ media. 
 
The following day, COS-7 cells were transfected with either the pSG5 hPXR or pcDNA 
zfPXR expression vector by the TransIT
®
-COS Transfection Kit (Mirus) (Table 3.1). Plates 
were resupplied with 14.5 mL of DMEM++ media. 15.5 µg of plasmids was added to 1.5 mL 
Opti-MEM I Reduced Serum Medium, followed by 46.5 µL TransIT-COS Reagent and 15.5 
µL COS Boss Reagent (COS reagents were warmed to room temperature and vortexed prior 
to use). Each plasmid mixture was then incubated at room temperature for 30 minutes before 
being distributed drop-wise to one of each culture plate. Four plates containing COS-7 cells 
without plasmids were maintained as a negative control. Cells were incubated overnight as 
described above. 
 
Table 3.1 
Experimental setup for the transfection of COS-cells. 
Transfection 
plasmid 
Cells/plate before 1 day 
before transfection 
Number 
of plates 
Ligand added to each plate 1 
day after transfection 
Negative 24.6 × 10
5
 4 None 
hPXR 24.6 × 10
5
 4 Rifampicin (5 µM) 
zfPXR 24.6 × 10
5
 4 Clotrimazole (5 µM) 
 
 
3.3.4 Nuclear and cytoplasmic fractionation from COS-7 cells 
Fractionation of subcellular components from eukaryotic cells is important when the 
localisation of protein is ambiguous, which is the case for PXR (reviewed in Zhou et al., 
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2009). Fractionation of both the cytoplasm and nuclei from transfected COS-7 cells allows 
for the immunochemical detection of PXR in each fraction. 
 
24 hours after transfection, all culture plates were replenished with 10 mL of DMEM++ 
media. 5 µM of rifampicin was added to COS-7 cells containing hPXR plasmids and 5 µM of 
clotrimazole was added to COS-7 cells containing zfPXR plasmids (Table 3.1). PXR agonists 
were added to induce the translocation of PXR to the nucleus (Kawana et al., 2003).  
 
24 hours after ligand treatment, culture plates were placed on ice and washed twice with 4 ºC 
PBS. Cells were then scraped into 1.5 mL centrifuge tubes using 1 mL 4 ºC PBS and 
centrifuged at 1000 × g for 2 minutes at 4 ºC. Hypotonic lysis was then carried out fractionate 
cellular components, where a high solute buffer is added to make cells swell and cell 
membranes burst due to an increase in osmotic pressure (Abmayr et al., 2006), but at the 
same time keep nuclei intact. The mixture was incubated in 300 µL of Buffer A for 10 
minutes at 4 ºC. The mixture was vortexed for 10 seconds then centrifuged at 1000 × g for 2 
minutes at 4 ºC. The supernatant containing the cytoplasmic fraction of the COS-7 cells was 
kept and frozen at –80 ºC. The addition of a second high-salt buffer causes the nuclear 
membrane to burst and so 300 µL of Buffer C was then added to the remaining cell pellet and 
incubated for 20 minutes at 4 ºC. The mixture was then centrifuged at 14000 × g for 3 
minutes at 4 ºC. The supernatant containing the nuclear fraction of the COS-7 cells was kept 
and frozen at –80 ºC. 
 
3.4 Prokaryotic protein expression for antigen production 
A prokaryotic cell line was also cultured to produce histidine-tagged zfPXR from the plasmid 
pET30b zfPXR (Figure 3.4). This vector encodes a 6×histidine tag (His-tag) fused to the full 
length Pxr protein and a gene encoding resistance to the antibiotic kanamycin. A small 
sample was obtained from a glycerol stock previously prepared by Roger Lille-Langøy. 
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Figure 3.4. Map of plasmid used in the prokaryotic expression of antigen. Plasmid 
pET30b His-tagged FL zfPXR had previously been transformed into E. coli Rosetta cells. LacI 
corresponds to the promoter region and kanamycin the antibiotic resistance gene. 
 
 
3.4.1 Expression culture of an E. coli cell line 
Prokaryotic protein expression is useful such that it can be induced to express recombinant 
protein in high quantities. One disadvantage is that the final protein product is often 
incorrectly folded post-translation, making it dysfunctional compared to its native state. 
 
E. coli Rosetta cells containing the pET30b His-tagged full length zfPXR were inoculated in 
a 5 mL starter culture of LB medium with 25 µg/mL of kanamycin and incubated at 37 ºC at 
250 rpm overnight. 
 
3.4.2 Protein induction 
The following day, 2-3 mL of the starter culture was transferred into 100 mL of LB medium 
with 25 µg/mL of kanamycin. The expression culture was incubated at 37 ºC at 250 rpm for 2 
hours before the cell density was determined spectrophotometrically (by its OD600). The 
OD600 corresponds to the optical density of the culture at 600 nm. Production of histidine-
tagged zfPXR was induced while the culture was in log phase growth (OD600 ≈ 0.6-0.8) by 
the addition of IPTG to make a final concentration of 0.5 mM. Just prior to induction, a 1 mL 
of pre-induced sample was collected, spun down at 2500 × g for 5 minutes and its pellet was 
frozen at –20 °C for protein analysis. The remainder of the culture was incubated at 15 ºC at 
250 rpm overnight. 
 
3.4.3 Cell lysis and protein extraction by sonication  
Unlike eukaryotes, prokaryotic cells require a more vigorous means of protein extraction. The 
presence of a cell wall means that shearing forces are often required to lyse cells. Sonication 
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is one means of achieving this, whereby ultrasonic frequencies are applied to cells in order to 
disrupt the cell membrane to achieve lysis. 
 
The following day, the OD600 was measured and 1 mL of sample was collected and its pellet 
obtained as described above. The culture was then harvested by centrifugation for at 2500 ×g 
for 5 minutes. The sample was resuspended with 15 mL PBS with 300 mM NaCl containing 
1 mg/mL lysozyme and 1 protease inhibitor tablet, before incubation at room temperature for 
5 minutes. The suspension was then lysed by sonication on ice with a 10 s ON 10 s OFF 
cycle for 5 minutes immediately followed by a 20 seconds ON 10 seconds OFF cycle for 
another 5 minutes. The lysate was centrifuged at 37,000 × g for 30 minutes at 4 °C to 
separate soluble and insoluble protein fractions. The supernatant was collected and the pellet 
was resuspended in 5 mL PBS with 300 mM NaCl containing 1× protease inhibitor. 1 mL of 
both the soluble and insoluble fraction were stored at –20 °C and saved for protein analyses. 
 
3.5 Protein analysis 
Protein analyses were carried out to confirm the induction and concentration of the PXR 
protein, and to immunochemically detect their immunoreactivity towards commercial 
antibodies and to hybridoma supernatants potentially containing monoclonal PXR antibodies. 
 
3.5.1 Quantification of total protein concentration by the Bradford protein assay 
The Bradford protein assay is a colorimetric test that utilises the staining agent coomassie 
brilliant blue (CBB) G-250 (Bradford, 1976). This compound binds to amines and causes a 
colour shift from red to blue when proteins are present. Measuring the absorbance at 595 nm 
allows for the correlation between the absorbance of the sample and protein concentration. 
Setting up a standard curve based on protein samples of known concentration allows one to 
determine the concentration of samples given its absorbance lies within the standard curve. 
 
The protein concentration from the cytoplasmic and nuclear fractions of transfected and non-
transfected COS-7 cells was determined using the Bradford protein assay. Samples from each 
fraction were also pooled maximise protein concentration. A standard concentration curve 
was constructed using bovine serum albumin (BSA) as a colour standard. 2000 µg/mL of 
BSA was prepared in both Buffer A and Buffer C, and diluted along a concentration gradient 
ranging from 0 µg/mL (blank) to 1500 µg/mL. At the same time, a 1:10 dilution of each 
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cytoplasmic and nuclear fraction was prepared. Bradford reagent was prepared by mixing 1 
part 17% phosphoric acid and 1 part CBB G-250. 4 µL triplicates of each standard and 
unknown were added into separate wells of a 96-well plate. 200 µL of bradford reagent was 
then added to each well and the mixture was shaken for 30 seconds and then incubated at 
room temperature for 15 minutes. The absorbance was measured at 595 nm using an 
EnSpire
®
 Multimode Plate Reader. The protein concentration of unknown samples was then 
extrapolated from a line of best as determined by the standard concentration curve. 
Background signal from all standards and unknowns was adjusted by subtracting the 
absorbance value from blank standards. 
 
3.5.2 Separation of protein by sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) 
SDS-PAGE is a method which separates proteins according to their size (Laemmli, 1970). 
This is achieved by first denaturing proteins using β-mercaptoethanol at high temperature, 
which reduces disulphide bonds. Denatured proteins are oriented into a linear shape by 
binding with an anionic detergent (SDS), which adds a constant negative charge along the 
polypeptide chain. An electrical current is then applied, causing smaller proteins to migrate 
further along a gel matrix towards the negative anode than larger proteins. 
 
The type of gel and the amount of sample loaded are described in Table 3.2. All samples 
were denatured in 1 × boiling buffer (containing β-mercaptoethanol) for 5 minutes at 95 ºC 
before being loaded into wells of an SDS mini-gel (7.5 × 8.5 × 0.75 mm). 5 µL of molecular 
weight standard (Precision Plus Protein™ Standards All Blue, BioRad) was added to each gel 
as a molecular weight standard. Gels were run in 1 × TGS buffer from 120 to 180 V and 
stopped when the boiling buffer had completely travelled through the gel. 
 
3.5.3 Visualisation of proteins in SDS-PA gels by coomassie staining 
Similar to the Bradford protein assay, coomassie staining involves the use of CBB R-250 to 
stain proteins. The exact binding nature of this chemical is not fully understood, but it is 
known to bind non-covalently with positively charged amine groups. A higher concentration 
of protein results in a higher number of bound dye molecules. The addition of a destaining 
agent (such as ethanol and acetic acid) is used to remove any unbound staining agent, leaving 
stained protein as chemically visible bands on the polyacrylamide gel. 
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After electrophoresis, polyacrylamide gels were briefly rinsed in deionised water to remove 
any excess SDS. Coomassie stain was then added and the gel was agitated slightly from one 
hour (room temperature) to overnight (4 ºC). The stained gel was then rinsed briefly in 
deionised water to remove any excess staining agent before being placed in destaining 
solution with slight agitation for 1 hour. The destaining solution was replaced when necessary 
until the gel became clear. The gel was rinsed again in deionised water before being viewed 
using a Gel Doc™ EZ Imager and ImageReady software (v3.0). 
 
Table 3.2 
Quantity of samples used for SDS-PAGE and the type of gel prepared. 
Sample Quantity loaded  Stacking gel (%) 
COS-7 cell lysate, cytoplasmic fraction 9 µg   10 
COS-7 cell lysate, nuclear fraction 9 µg  10 
hPXR, cytoplasmic fraction 9 µg  10 
hPXR, nuclear fraction 9 µg  10 
zfPXR, cytoplasmic fraction 9 µg  10 
zfPXR, nuclear fraction 9 µg  10 
Hybdridoma supernatants 8 µL  12.5 
Hybridoma supernatant wash 8 µL  12.5 
IgG-enriched hybridoma supernatant 8 µL  12.5 
E. coli Rosetta cells 12 µL, OD600 = 1.0
*
  10 
Pre-induced E. coli Rosetta cells with His-tagged 
zfPXR 
12 µL, OD600 = 1.0  10 
Post-induced E. coli Rosetta cells with His-tagged 
zfPXR 
12 µL, OD600 = 1.0  10 
Supernatant of lysed E. coli Rosetta cells with His-
tagged zfPXR  
1.8 µL
†
  10 
Pellet of lysed E. coli Rosetta cells with His-tagged 
zfPXR 
1.35  µL
‡
  10 
* In order to obtain an OD600 = 1.0 culture, 100 µL OD600 = 1.40 of cells for example was concentrated to 
71.4 µL. 
† Given that the supernatant containing the soluble fraction was × 6.66 times smaller in volume than the 
post-induced culture, then the volume required to equal 12 µL OD600 = 1.00 would be 1.8 µL 
‡ Given that the supernatant containing the insoluble fraction was × 1.33 times smaller in volume than the 
supernatant containing the soluble fraction, the volume required to equal 12 µL OD600 = 1.00 would be 
1.35 µL. 
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3.5.4 Immunochemical detection of proteins by Western blotting 
Western blotting (WB) is a method which transfers proteins from a polyacrylamide gel to a 
membrane (polyvinylidene fluoride, PDVF) through an electrical current (Towbin et al., 
1979). Proteins transferred to the membrane can then be detected immunochemically using 
antibodies (Figure 3.5). First, the membrane is then blocked with proteins (such as milk) to 
prevent the non-specific binding of antibodies to the membrane. Primary antibodies specific 
to an epitope of the protein of interest are then added. Secondary antibodies specific to an 
epitope of the primary antibody are added. In this study, secondary antibodies were 
conjugated with horseradish peroxidase (HRP), an enzyme that converts a luminogenic 
substrate into a product which emits chemiluminescent light at a wavelength of 430 nm. This 
process is referred to as enhanced chemiluminescence (ECL). This light can then be detected 
using a CCD camera, and immunoreactive proteins will appear as a dark band using image 
processing software. 
 
       
Figure 3.5. Representation of immunochemical detection of an immunoreactive protein transferred 
to a membrane by WB. Image adapted from Bio-Rad (2014). 
 
 
3.5.4.1 Transfer of proteins from SDS-PAG to PDVF membranes 
Various methods exist for WB, and two common methods used are semi-dry and wet blotting 
transfer. Semi-dry transfer involves the transfer of proteins in membrane and filter paper pre-
soaked in a transfer buffer. It is faster and requires less transfer buffer, but is less efficient at 
transferring larger proteins. Wet blotting on the other hand transfers proteins immersed in the 
transfer buffer. It requires more time and a larger volume of transfer buffer, and is susceptible 
to overheating. Both types of blotting were used in this study. 
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The details for each type of Western blot transfer are detailed in Table 3.3. Proteins run 
through SDS-PAGE were transferred to a PDVF membrane using either the semi-dry or wet 
transfer method. For both types of transfer, PDVF membranes were activated in 100% 
methanol for 15 seconds before being transferred into water for 2 minutes and then into 
transfer buffer for 10-15 minutes. Semi-dry transfer was carried out in a Trans-Blot
®
 SD 
Semi-dry Transfer cell (Bio-Rad) at 15 V for 25 minutes, and wet transfer at 100 V for 1 hour 
with an ice block to reduce overheating. Coomassie staining was carried out on the 
polyacrylamide gel after transfer to ensure successful protein transfer to the membrane. 
 
Membranes were blocked in either PBS or TBS-T buffer containing 5% non-fat dry milk with 
slight agitation for one hour at room temperature (buffers used listed in Table 3.3). 
Membranes were washed in buffer two to four times for 5 minutes before being incubated 
with a primary antibody (diluted in buffer with 5% non-fat dry milk) with slight agitation 
overnight at 4 ºC. The following day, the membrane was washed four times with buffer for 5 
minutes, then incubated with a secondary antibody (diluted in buffer with 5% non-fat dry 
milk) with slight agitation from one to two hours at room temperature. The membrane was 
then washed in buffer two to four times for 5 minutes. 
 
3.5.4.2 Visualisation of immunoreactive proteins by horseradish peroxidase (enhanced 
chemiluminescence) 
The probed PDVF membrane was then exposed to either the Amersham™ ECL™ Prime 
Western Blotting Detection Reagent (GE Healthcare) or the SuperSignal
®
 West Pico 
Chemilumiscent Substrate (Thermo Scientific) (Table 3.3). For membranes exposed to the 
Amersham kit, the reagent was prepared as described in the protocol and added dropwise to 
the membrane and left to incubate for 5 minutes. Excess reagent was removed and the 
membrane was viewed using a ChemiDoc™ XRS+ imager and ImageReady software (v5.1). 
For membranes exposed to SuperSignal kit, reagent was prepared and added in the same 
manner, but an incubation step was omitted due to the sensitivity of the kit.
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Table 3.3 
Concentration of test antigens loaded for WB blotting and dilutions of commercial primary antibody and secondary antibodies used to detect 
immunoreactivity. 
Sample Quantity loaded Transfer method Buffer used Primary antibody Secondary antibody Detection kit 
COS-7 cell lysate, cytoplasmic 
fraction 
1 µg/mm
*
 Semi-dry PBS 1:1000 anti-
hPXR 
1:4000 anti-mouse  
IgG HRP-conjugated 
Amersham 
COS-7 cell lysate, nuclear fraction 1 µg/mm Semi-dry PBS 1:1000 anti-
hPXR 
1:4000 anti-mouse 
IgG HRP-conjugated 
Amersham 
hPXR, cytoplasmic fraction 1 µg/mm Semi-dry PBS 1:1000 anti-
hPXR 
1:4000 anti-mouse 
IgG HRP-conjugated 
Amersham 
hPXR, nuclear fraction 1 µg/mm Semi-dry PBS 1:1000 anti-
hPXR 
1:4000 anti-mouse 
IgG HRP-conjugated 
Amersham 
zfPXR, cytoplasmic fraction 1 µg/mm Semi-dry PBS 1:1000 anti-
hPXR 
1:4000 anti-mouse 
IgG HRP-conjugated 
Amersham 
zfPXR, nuclear fraction 1 µg/mm Semi-dry PBS 1:1000 anti-
hPXR 
1:4000 anti-mouse 
IgG HRP-conjugated 
Amersham 
E. coli Rosetta cells OD600 = 1.0/5 mm
†
 Wet TBS-T 1:4000 anti-His 1:10000 anti-mouse 
IgG HRP-conjugated 
SuperSignal 
Pre-induced E. coli Rosetta cells 
with His-tagged zfPXR 
OD600 = 1.0/5 mm Wet TBS-T 1:4000 anti-His 1:10000 anti-mouse 
IgG HRP-conjugated 
SuperSignal 
Post-induced E. coli Rosetta cells 
with His-tagged zfPXR 
OD600 = 1.0/5 mm Wet TBS-T 1:4000 anti-His 1:10000 anti-mouse 
IgG HRP-conjugated 
SuperSignal 
Supernatant of lysed E. coli Rosetta 
cells with His-tagged zfPXR  
0.36 µL/mm
‡
 Wet TBS-T 1:4000 anti-His 1:10000 anti-mouse 
IgG HRP-conjugated 
SuperSignal 
Pellet of lysed E. coli Rosetta cells 
with His-tagged zfPXR 
0.27 µL/mm
×
 Wet TBS-T 1:4000 anti-His 1:10000 anti-mouse 
IgG HRP-conjugated 
SuperSignal 
* 1 µg/mm corresponds to 1 µg of sample loaded per the length of the well. For example, combs with wells 5 mm long were loaded with 5 µg of sample and wells 70 
mm long were loaded with 70 µg of sample. 
† Given that 12 µL OD600 = 1.0of sample was loaded into a 5 mm well, then wells 70 mm long were loaded with 168 µL OD600 = 1.0. 
‡ Given that 1.8 µL of sample was loaded into a 5 mm well, then wells 70 mm long were loaded with 126 µL of sample. 
× Given that 1.35 µL of sample was loaded into a 5 mm well, then wells 70 mm long were loaded with 126 µL of sample.
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3.6 Screening of hybridoma supernatants for immunoreactivity 
After determining it was possible to probe PXR orthologs (or fused proteins) with 
commercial antibodies, characterisation of monoclonal antibodies was carried out using 
supernatants from hybridoma cultures established by fusing of splenocytes and myeloma 
cells from mice immunised with human and zebrafish PXRs (as described in Richard 
Davies’s Master’s thesis, 2011, listed in Materials 2.7 of this thesis). 
 
3.6.1 IgG enrichment of hybridoma supernatants 
The Protein G HP SpinTrap
TM
 (GE Healthcare) was used to obtain IgG-enriched antibodies 
from hybridoma supernatants. Antibodies were purified in a spin column containing 
sepharose resin, a compound which covalently binds to cysteine side chains at slightly basic 
pH values (Björck and Kronvall, 1984). Decreasing pH reduces the sepharose’s affinity 
towards antibodies, thus allowing their extraction through a low pH eluent. 
 
Samples were loaded into the spin column as described by the protocol. Ten volumes of 600 
µL of hybridoma supernatant were loaded through the column followed by a wash step until 
6 mL of sample had been passed through the column. After purification, spin columns were 
rinsed twice with 400 µL of elution buffer and then twice with 400 µL of 20% ethanol before 
a new batch of hybridoma supernatant was eluted through the column. 
 
3.6.2 Screening the immunoreactivity of hybridoma supernatants using PXR antigen 
Eukaryotically expressed hPXR and zfPXR, and prokaryotically expressed His-tagged zfPXR 
were immunochemically detected with hybridoma supernatants of different dilutions as well 
with IgG-enriched supernatants as described in Table 3.4. Each of type of antigen samples 
were subjected to SDS-PAGE and transferred to PVDF membrane (Methods 3.5.2 and 
3.5.4.1). After transfer, the membrane was left to completely dry before being cut into 3 mm 
wide strips. The remainder were stored at –25 ºC. 
 
 38 
 
Table 3.4 
Concentration of antigens loaded for WB blotting and dilutions of unpurified and IgG-enriched hybridoma supernatants and secondary antibodies used to 
detect immunoreactivity. 
Sample Quantity loaded Transfer method Buffer used Hybridoma supernatant Secondary antibody Detection kit 
COS-7 cell lysate, cytoplasmic 
fraction 
1 µg/mm
*
 Semi-dry PBS 1:1, 1:10, 1:100, 1:1000 
hybridoma supernatant 
1:1000 anti-mouse 
IgG HRP-conjugated 
Amersham 
hPXR, cytoplasmic fraction 1 µg/mm Semi-dry PBS 1:1, 1:10, 1:100, 1:1000 
hybridoma supernatant 
1:1000 anti-mouse 
IgG HRP-conjugated 
Amersham 
zfPXR, cytoplasmic fraction 1 µg/mm Semi-dry PBS 1:1, 1:10, 1:100, 1:1000 
hybridoma supernatant 
1:1000 anti-mouse 
IgG HRP-conjugated 
Amersham 
COS-7 cell lysate, cytoplasmic 
fraction 
1 µg/mm Semi-dry PBS 1:50 IgG-enriched 
supernatant 
1:2000 anti-mouse 
IgG HRP-conjugated 
Amersham 
hPXR, cytoplasmic fraction 1 µg/mm Semi-dry PBS 1:50 IgG-enriched 
supernatant 
1:2000 anti-mouse 
IgG HRP-conjugated 
Amersham 
zfPXR, cytoplasmic fraction 1 µg/mm Semi-dry PBS 1:50 IgG-enriched 
supernatant 
1:2000 anti-mouse 
IgG HRP-conjugated 
Amersham 
E. coli Rosetta cells OD600 = 1.0/5 mm
†
 Wet TBS-T 1:1 hybridoma 
supernatant 
1:10000 anti-mouse 
IgG HRP-conjugated 
SuperSignal 
Pellet of lysed E. coli Rosetta 
cells with His-tagged zfPXR 
0.27 µL/mm
×
 Wet TBS-T 1:1 hybridoma 
supernatant 
1:10000 anti-mouse 
IgG HRP-conjugated 
SuperSignal 
E. coli Rosetta cells OD600 = 1.0/5 mm
†
 Wet TBS-T 1:50 IgG-enriched 
supernatant 
1:10000 anti-mouse 
IgG HRP-conjugated 
SuperSignal 
Pellet of lysed E. coli Rosetta 
cells with His-tagged zfPXR 
0.27 µL/mm
×
 Wet TBS-T 1:50 IgG-enriched 
supernatant 
1:10000 anti-mouse 
IgG HRP-conjugated 
SuperSignal 
* 1 µg/mm corresponds to 1 µg of sample loaded per the length of the well. For example, combs with wells 5 mm long were loaded with 5 µg of sample and wells 70 
mm long were loaded with 70 µg of sample. 
† Given that 12 µL OD600 = 1.0of sample was loaded into a 5 mm well, then wells 70 mm long were loaded with 168 µL OD600 = 1.0. 
‡ Given that 1.8 µL of sample was loaded into a 5 mm well, then wells 70 mm long were loaded with 126 µL of sample. 
× Given that 1.35 µL of sample was loaded into a 5 mm well, then wells 70 mm long were loaded with 126 µL of sample.
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PDVF membrane strips of containing protein extract were blocked as described (Methods 
3.5.4.2) and incubated with their respective hybridoma supernatants containing primary 
antibody and then secondary antibodies diluted in buffer (Table 3.4). Membrane strips were 
also washed between each step. Both the Amersham and SuperSignal kits were used to detect 
the presence of monoclonal antibodies from each hybridoma supernatant responding to PXR 
orthologs. Membranes were viewed using a ChemiDoc™ XRS+ imager and ImageReady 
software (v5.1). 
 
3.7 Exposure experiment of zebrafish to clotrimazole 
An initial effort was made to conduct an exposure experiment on both embryonic and adult 
zebrafish, extraction of total RNA from individuals, sequencing of the pxr gene to identity 
allelic variants and quantification of expression of a zfPXR target gene, cyp3a65. Due to time 
limitations this final goal was not achieved, however total RNA extraction was carried out on 
a small number of adult and embryo zebrafish, and pxr was sequenced from 24 individuals. 
 
3.7.1 Rearing of adult zebrafish 
Adult zebrafish (strain AB/Tu) were maintained at the zebrafish facility at the Institute of 
Biology at the University of Bergen in accordance with FOTS application 5799. Male and 
female adults (age = 335 to 809 days) were reared from cross breeding and maintained in 
water from the zebrafish facility at 28° C on a 14: 10 hour day: night cycle and fed ad libitum 
Artemia salina with ST-3 daily. Some of the adults were mated for embryo collection, the 
methods of which are described below. 
 
3.7.2 Adult exposure experiment 
Adult zebrafish (n = 160) were used for an exposure experiment. 20 adults were allocated to 
one of eight tanks, four representing control and four representing treatment (Table 3.5). Each 
tank contained 4 L of water from the zebrafish facility and 50% of this water was changed 
daily. Fish were left to acclimatise for 2 days after transfer to exposure tanks before 
beginning the exposures. On the third day, 0.25% DMSO was added to the control tanks and 
1 µM clotrimazole dissolved in DMSO (final concentration of 0.25%) was added to the 
treatment tanks. On the fourth day, 50% of the treated water was replaced. 48 hours after 
exposure, zebrafish were anaesthetised in 200 mg/L tricaine mesylate and their livers were 
excised under a Nikon SMZ-645 stereomicroscope. Livers were snap frozen in liquid  
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Table 3.5 
Experimental setup for the exposure of zebrafish adults. 
Number of zebrafish Fish per tank Volume (L) Treatment 
80 20 4 0.25% DMSO control 
80 20 4 1 µM clotrimazole, 0.25% DMSO 
 
 
nitrogen, stored at –80 ºC and used for subsequent experiments. Weight, sex and any deaths 
during the exposure experiment were also noted. 
 
3.7.3 Embryo collection 
Ten male and ten female zebrafish adults were acclimated in the same tank for 24 hours, with 
a visible barrier separating the sexes. After the 24 hour period, the barrier was removed 
allowing males and females to mate, lay and fertilise eggs for up to one hour. Males and 
females were then returned to their respective tanks and eggs were collected using a sieve. 
Eggs were sorted onto a Petri dish and incubated in E3 medium overnight at 28.5 °C. 
 
3.7.4 Embryo exposure experiment 
Throughout the exposure experiment, all embryos were reared in E3 medium at 28.5 °C in a 
dark incubator. At 24 hours post fertilisation (hpf), any unfertilised eggs were discarded. At 
48 hpf, eggs were checked again and allocated to one of two Petri dishes, one representing 
control and one representing treatment (Table 3.6). 1% DMSO was added to the control dish 
and 1 µM clotrimazole in 1% DMSO was added to the treatment dish. At 72 and 96 hpf, 50% 
of the treated medium was replaced and any hatched eggshells, debris or dead individuals 
were also removed. At 120 hpf, individual embryos were transferred to 1.5 mL centrifuge 
tubes. The treated water was removed completely and each tube was then snap frozen in 
liquid nitrogen and stored at –80 °C. 
 
Table 3.6 
Experimental setup for the exposure of zebrafish embryos. 
Number of zebrafish Embryos per dish Volume (mL) Treatment 
60 60 30 1% DMSO control 
60 60 30 1 µM clotrimazole,  1% 
DMSO 
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3.8 RNA extraction 
Messenger RNA (mRNA) is more convenient to extract from biological samples than DNA 
due to its lack of introns, but ribonucleases (RNases) can become a major source of 
interference. Total RNA was extracted from select adult livers and individual embryos using 
different methods. 
 
3.8.1 Total RNA extraction from adult zebrafish livers 
Acid guanidinium thiocyanate-phenol-chloroform extraction is a commonly used method to  
extract RNA from homogenised sample (Chomczynski and Sacchi, 1987). Guanidinum 
thiocyanate is used to denature RNases  (Gordon, 1972), and water-saturated phenol and 
chloroform are used separate the homogenate into three phases: an aqueous phase containing 
RNA; an interphase containing DNA an organic phase containing proteins and lipids. 
 
Total RNA was extracted from the liver tissue of adult zebrafish using the TRI Reagent
® 
(Sigma Aldrich) protocol as described by Sigma Aldrich. RNA was extracted from two single, 
and pools of five and nine individuals. RNA was resuspended in 100 µL RNase-free water 
(Qiagen) and its concentration was determined by spectrophotometry (Methods 3.2.3). 
 
3.8.2 Denaturing agarose gel electrophoresis 
Because RNA commonly forms secondary structures and is susceptible to degradation, a 
denaturing agent is required to keep the nucleic acids stable (Masek et al., 2005). Denaturing 
AGE allows for the preparation and evaluation of intact RNA. In eukaryotes, intact RNA 
subject through denaturing AGE is indicated by the presence of heavy 28S and light 18S 
ribosomal RNA (rRNA). 
 
RNA was denatured in 50% formamide containing 1 × loading buffer and heated to 65 ºC for 
10 minutes. 100-200 ng of each sample and 2-log DNA ladder were loaded onto gels 
containing 1% agarose in 1 × TAE buffer and 50 µg/mL of EtBr. Gels were run and 
visualised as previously described (Methods 3.2.4). 
 
3.8.3 Total RNA extraction from individual embryos 
RNA extraction was conducted in accordance to the protocol developed by de Jong et al. 
(2010). Initially, centrifuge tubes containing individual embryos were transferred from –
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80 °C to liquid nitrogen prior to homogenisation. A stainless steel pestle (Carl Roth) was pre-
chilled in liquid nitrogen and then connected to a XENOX motorised hand tool. Each embryo 
was crushed at about 5000 rpm for 5-10 seconds. The pestle was lifted slightly and 200 µL of 
QIAzol
® 
Lysis Reagent (Qiagen) was added. After the homogenate had been allowed to thaw, 
an additional 100 µL of lysis reagent was added to wash the pestle. Alternative methods, such 
as the use of TRI Reagent and types of pestles were also considered and are detailed in Table 
3.7. After the optimal conditions were determined, TRI Reagent was used for the remainder 
of RNA extractions. The homogenate was vortexed for 15 seconds and left at room 
temperature for 5 min. Homogenates were spun down for 15 seconds before 60 µL of 24:1 
chloroform : isoamyl alcohol was added. The homogenate was vortexed again for 15 s, left at 
room temperature for 3 min and spun down for 15 s. The entire homogenate was added to 
individual tubes containing 75-100 mg of heavy phase-lock gel (HPLG), which beforehand 
had been centrifuged at 12,000 × g for 30 seconds. The homogenate and gel was then 
centrifuged 12,000 × g for 15 minutes and the clear, aqueous phase was transferred to a new 
1.5 mL centrifuge tube. Some sample was collected for use in a gel electrophoresis. Total 
RNA from adult zebrafish livers (500–4000 ng) was also run through the extraction to 
determine the yield of the method. 
 
Table 3.7 
Different methods used for total RNA extraction from individual embryos. 
Pestle type Pre-chilled? Lysis reagent 
Plastic No QIAzol 
Plastic Yes (–80 °C) QIAzol 
Metal Liquid nitrogen QIAzol 
Metal Liquid nitrogen  TRI Reagent 
 
 
3.8.4 RNA cleanup using the RNA MinElute kit 
After collecting the aqueous phase of the homogenate after HPLG separation, RNA cleanup 
was carried out in a silica-membrane column. The silica-membrane has a high affinity for 
RNA, and various wash steps with ethanol and buffer were used to remove contaminants 
such as phenol or proteins. RNA is disassociated from the column after a final high speed 
centrifugation step and collected in RNase-free eluent. 
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RNA was cleaned according to the RNA
®
 MinElute
TM 
Cleanup Kit (Appendix D of the 
QIAGEN protocol). In short, 1 volume of 70% ethanol was added to the RNA and the 
mixture was vortexed thoroughly. The volume was transferred to an RNeasy MinElute spin 
column and centrifuged at 8,000 × g for 15 s. 500 µL of RPE buffer was added and the 
column was centrifuged at 8,000 × g for 15 seconds. 500 µL of 80% ethanol was added and 
the column was centrifuged at 8,000 × g for 2 minutes. The column was then centrifuged at 
14,000 × g for 5 minutes. 14 µL of RNase-free water was added to the centre of the column 
and centrifuged at 14,000 × g for 1 min. The eluate was added to the column a second time in 
order to maximise RNA yield. During two extractions of total RNA from individual embryos, 
flow-through was collected at each step and to determine whether any RNA was being lost 
during the cleanup process. Total RNA from adult zebrafish livers (500–4000 ng) was also 
initially subjected through RNA cleanup to determine the recovery of RNA. 
 
RNA concentration from each individual was quantified using the NanoDrop
®
 ND 1000 
spectrophotometer (Methods 3.2.3), and the integrity of each sample was verified using 
denaturing AGE (Methods 3.8.2). 
 
3.9 Sequencing of allelic variants of pxr in zebrafish 
After successfully extracting total RNA from individual embryos, cDNA was synthesised 
from mRNA, the zebrafish pxr gene was amplified and then sequenced. 
 
3.9.1 cDNA synthesis 
Reverse transcription of mRNA to cDNA was carried out using oligo-dT primers which binds 
to the poly-A tail of mRNA. A qScript reverse transcriptase (RT) consists of a Moloney 
Murine Leukemia Virus Reverse Transcriptase (M-MLV RT) and RNase inhibitor protein, 
allowing for the synthesis of high quality cDNA with long mRNA templates. 
 
The synthesis of cDNA was carried out according to the protocol by the qScript
TM
 cDNA 
Synthesis Kit (Quanta Biosciences). 500 ng of total RNA was reverse transcribed to cDNA 
using the qScript RT enzyme. The reaction was carried out in a total volume of 20 µL. 
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3.9.2 Polymerase chain reaction 
The polymerase chain reaction (PCR) is a well-established method that amplifies DNA 
fragments through the use of primers which recognise the desired ends of the fragment 
sequence (Mullis and Faloona, 1987). PCR amplification involves denaturation, annealing 
and extension steps along with the thermostable enzyme, DNA polymerase (Saiki et al., 
1988). In this study, PrimeSTAR
®
 GXL DNA Polymerase was chosen as an enzyme for PCR 
amplification since it is reported to have a high fedility (i.e. accurate replication of the 
template). Amplification was carried out on beta-actin, in order to determine the success of 
cDNA synthesis (0.6 kb) and primers to produce a full-length zebrafish pxr amplicon to be 
used as template in sequencing (1.1 kb). 
 
PCR reactions were set up and run according to Tables 3.8 and 3.9. For each reaction, a 
negative control containing no template was also prepared along with a positive control 
containing 20 ng of the pcDNA zfPXR plasmid. These controls were set up to ensure no 
contamination was occurring and that the PCR reaction was successful. 3 µL of each PCR 
product was run on a 1% agarose gel in 1 × TAE buffer for 110 V for 35 min on ice and 
analysed on a Gel Doc™ EZ Imager and ImageReady software (v3.0). 
 
Table 3.8 
PCR reaction mixture components. 
Component Final concentration Volume (µL) 
5× PrimeSTAR GXL Buffer 1 × 10 
dNTP Mixture 200 µM each 4 
Forward Primer  0.25 µM 2.5 
Reverse Primer  0.25 µM 2.5 
Template cDNA (from 500 ng RNA)  2 
PrimeSTAR GXL DNA Polymerase 1.25 U/50 µL 1 
Deionised water  28 
Total  50 
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Table 3.9 
PCR reaction settings. 
Temperature (° C) Time Cycles 
   
98 10 s  
55 15 s 32 
68 1 min/kb  
4 ∞  
 
 
PCR product was cleaned according to the protocol of a PCR cleanup kit from Sigma Aldrich. 
Samples were collected in 50 µL of elution solution and PCR product concentration was 
measured using a NanoDrop
®
 ND 1000 spectrophotometer. 100 ng of each sample was 
subjected to AGE (Methods 3.2.4, 1% agarose gel, 1 × TAE, 110 V for 35 min on ice) and 
analysed on a Gel Doc™ EZ Imager and ImageReady software (v3.0). 
 
3.9.3 Sanger sequencing 
Sanger sequencing is a method that utilises chain-terminating dideoxynucleotides (ddNTPs) 
in the presence of DNA polymerase (Sanger et al., 1977). Dye-terminating ddNTPs contain 
four different fluorescent labels (ddA, ddC, ddG and ddT) which emit light at different 
wavelengths, allowing for the determination of nucleotide base pair along a given sequence. 
 
10-40 ng of purified PCR product per sample was used as template in the sequencing 
reactions. Forward and reverse primers were selected to flank nucleotides 478 to 1070 in the 
zebrafish pxr gene because this region has been found to contain two non-synonymous 
mutations in zebrafish (Bainy et al., 2013). A reaction mixture was prepared and run for each 
sample containing a forward and reverse primer (Table 3.10 and 3.11). After the reaction, an 
additional 10 µL of deionised water was added to reaction tube and samples were sequenced 
using the 3730XL DNA Sequencer (Applied Biosystems). 
 
Chromatograms of each forward and reverse sequence were visualised in ApE (v2.0.47) and 
translated to amino acids. Consensus DNA sequences (contigs) were created from the 
forward and reverse sequences of each individual using BioEdit (v7.1.3.0). Sequences were 
aligned using ClustalW and visualised in JalView (v2.8.0b1). 
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Table 3.10 
Sequencing reaction mixture components. 
Component Final concentration Volume (µL) 
BigDye v3.1 1 × 1 
Sequencing buffer 1 × 1 
Template 20-40 ng 2 
Primer 320 nM 1 
Betaine 5 M 1 M 2 
Deionised water  3 
Total  10 
 
 
Table 3.11 
Reaction settings for sequencing. 
Temperature (° C) Time Cycles 
96 5 min 1 
96 10 s  
50 5 s 35 
60 4 min  
4 ∞  
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4. Results 
 
4.1 Characterisation of antibodies against PXR orthologs 
Supernatants from hybridoma cultures were tested against human and zebrafish PXRs in 
order to determine their immunoreactive properties (Methods 3.6). This involved the 
eukaryotic and prokaryotic expression and evaluation of an antigen used to test the 
immunoreactivity of commercial antibodies and of the hybridoma supernatants (see Figure 
3.1 for experimental overview). 
 
4.1.1 Production and evaluation of the PXR antigen in COS-7 cells 
Supercoiled plasmids were required in order for an efficient transfection into a eukaryotic cell 
line. This involved the transformation of plasmids into a prokaryotic cell line, incubation, 
purification and gel electrophoresis to confirm their topology (Methods 3.2, Figure 4.1). 
Since plasmids are capable of coiling, circular plasmids often do not travel through a gel 
according to size alone but also according to their topology. As a result, the circular plasmids 
which have travelled further through a gel are more supercoiled than those preceding them. 
The pure pSG5 hPXR and pcDNA zfPXR plasmid DNA obtained consisted mostly of 
plasmids of supercoiled topology (Figure 4.1). 
 
 
Figure 4.1. Evaluation of plasmid topology by agarose gel electrophoresis. The plasmids 
were pSG5 hPXR (lane 1) and pcDNA zfPXR (lane 2). 200 ng of 2-log DNA ladder and sample were 
subjected to AGE (0.7% agarose in 0.5 × TBE buffer for 35 min at 110 V). 
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The pSG5 hPXR and pcDNA expression vectors were transiently transfected into the COS-7 
eukaryotic cell line (Methods 3.3). Endogenous PXR has been reported to translocate to the 
nucleus upon activation (Kawana et al., 2003), so transfected COS-7 cells were exposed to 
well known agonists of human and zebrafish PXRs (rifampicin and clotrimazole respectively). 
However, it is not known whether recombinantly expressed PXR translocates in a similar 
manner to endogenous PXR, so both the cytoplasmic and nuclear fractions were collected 
from COS-7 cells. The Bradford protein assay was then used to determine the concentration 
of total protein within each sample (Methods 3.5.1). Total protein concentration varied 
between each fraction, but a much higher quantity of protein was found in non-transfected 
COS-7 cells than in those transfected with plasmids (Table A1, Appendix A). 
 
5 µg of total protein from each fraction was subjected to SDS-PAGE and proteins were 
visualised by coomassie staining (Methods 3.5.2-3, Figure 4.2). Stained proteins appeared 
more intact in the cytoplasmic fraction of COS-7 cells than in the nuclear fraction. Despite 
this, Western blotting was still carried out on all samples (Methods 3.5.4.1). Samples were 
probed with a commercial anti-hPXR primary antibody before immunodetection with an 
HRP-conjugated secondary antibody (Methods 3.5.4.2, Figure 4.3). In both the cytoplasmic 
and nuclear fractions, an immunoreactive protein corresponding to a size of approximately 50 
kD was detected, consistent with the size of human PXR. No immunoreactivity was detected 
for the non-transfected COS-7 cells and those transfected with zfPXR, indicating that the 
anti-hPXR antibody most likely did not cross-react with zebrafish Pxr, or with any 
endogenous PXR present in the COS-7 cells. Due to the lack of commercial antibody 
available for zfPXR, it was not possible at this stage to determine whether COS-7 cells had 
been successfully transfected with zfPXR or whether they were expressing a sufficient 
quantity of antigen for detection. Because the cytoplasmic fractions contained more intact 
protein and a higher concentration of immunoreactive protein, these samples were used to test 
the immunoreactivity of the hybridoma supernatants. 
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Figure 4.2. Separation of COS-7 protein fractions by SDS-PAGE. 5 µg of cytoplasmic and 
nuclear proteins were separated by SDS-PAGE and visualised by CBB staining. M represents 5 µL of 
the molecular weight standard; lanes 1–3 represent the cytoplasmic fraction of COS-7 cells 
transfected with: no plasmid, hPXR and zfPXR respectively; lanes 4–6 represent the nuclear fraction 
of cells transfected with: no plasmid, hPXR and zfPXR respectively. 
 
 
 
Figure 4.3. Immunochemical detection of immunoreactive protein in COS-7 fractions. 
Western blot of 5 µg of COS-7 cell cytoplasmic (lanes 1–3) and nuclear fractions (lanes 4–6) on a 
PDVF membrane. M the molecular weight standard; lanes 1 and 4 correspond to non-transfected 
COS-7 cells; lanes 2 and 5 correspond to cells transfected with hPXR; and lanes 3 and 6 to cells 
transfected with zfPXR. The membrane was probed with mouse anti-hPXR monoclonal IgG primary 
antibody (1:1000) and detected with a goat anti-mouse IgG HRP-conjugated secondary antibody 
(1:4000). Chemiluminescence was detected with the Amersham™ ECL™ Prime kit. 
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4.1.2 Immunoreactivity of unpurified hybridoma supernatants 
In a previous Master’s project, eight hybridoma cultures suspected to be secreting anti-PXR 
antibodies were identified (Davies, 2011). Final cell lines were selected according to their 
highest reactivity against a test antigen and the immunoreactivity of these was verified by 
immunochemically. In this study, six of the eight hybridoma supernatants chosen had 
previously not been tested for their immunoreactivity and the other two had only been tested 
with a lower quality of the PXR antigen. 
 
The immunoreactivity of selected hybridoma supernatants potentially containing monoclonal 
antibodies specific to either hPXR or zfPXR was tested by chemical immunodetection against 
each cytoplasmic fraction of the COS-7 cells (Methods 3.6.2). Membranes were cut into 3 
mm strips in order to probe the same protein with multiple hybridoma supernatants. Initially, 
only some of the supernatants were tested immunochemically (data not shown). However, an 
oversaturation of antibodies present in the supernatant made it difficult to separate signal 
from background noise, and so dilutions of select hybridoma supernatants were prepared and 
probed against each cytoplasmic fraction (Figure 4.4). Human PXR has a molecular weight 
of approximately 50 kD, but immunoreactive proteins corresponding to an unexpected size of 
at 55 kD were detected in the cytoplasmic fraction of cells expressing both human and 
zebrafish PXRs, as well as with the negative control. 
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Figure 4.4. Immunochemical detection of diluted hybridoma supernatants. WB of 1 
µg/mm of COS-7 cell cytoplasmic fraction on a PDVF membrane corresponding to: non-transfected 
COS-7 cells, cells transfected with hPXR, and cells transfected with zfPXR (Methods 3.5). 
Membranes were cut into 3 mm strips and probed with hybridoma supernatant 5E4F9D9 from cells of 
mice immunised with hPXR (1:10, 1:100, 1:1000); and hybridoma supernatant 9E11D2C4 immunised 
with zfPXR  (1:10, 1:100, 1:1000) and then detected with polyclonal goat anti-mouse IgG HRP-
conjugated secondary antibodies (1:1000). Chemiluminescence was detected with the Amersham™ 
ECL™ Prime kit. 
 
 
4.1.3 Immunoreactivity of IgG-enriched hybridoma supernatants 
In order to increase antibody concentration and reduce background noise from potentially 
cross-reacting species present within the unpurified hybridoma supernatants, the Protein G 
HP SpinTrap
TM
 was used to enrich the quantity of IgG antibodies present in each supernatant 
(Methods 3.6.1). 6 mL of hybridoma supernatant was upconcentrated to a final volume of 
400 µL. To evaluate this enrichment, each hybridoma supernatant, eluate wash and IgG-
enriched hybridoma supernatant were subjected to SDS-PAGE and visualised by coomassie 
staining (Figure 4.5). The disulphide-linked heavy and light chains of an antibody become 
disassociated when the immunoglobulin is denatured and treated with β-mercaptoethanol, and 
so proteins migrating to a size of approximately 50 kD correspond to the heavy chain and 
approximately 25 kD to the light chain respectively. Proteins corresponding to the heavy 
chain of an IgG antibody were present in all samples, however proteins corresponding to the 
light chain were only observed in the unpurified hybridoma supernatants. In addition, the 
light chain-sized proteins were also visualised at lower quantities compared to the heavy 
chain bands at 50 kD. Protein concentration also appeared to decrease during the enrichment 
process, with the IgG-enriched hybridoma supernatants showing a lower concentration of  
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Figure 4.5. Evaluation of hybridoma supernatants subjected through IgG enrichment. 8 
µL of each unpurified hybridoma supernatant (S), eluate wash (W) and IgG-enriched supernatant (P) 
was separated by SDS-PAGE and visualised by CBB staining. M represents 5 µL of the molecular 
weight standard; lanes 1–5 correspond to hybridoma supernatants containing hPXR and lanes 6–8 
zfPXR. Within each lane, sublane 1 corresponds to unpurified hybridoma supernatant, sublane 2 the 
eluate wash and sublane 3 the IgG-enriched hybridoma supernatant. 
 
 
total protein compared to the unpurified supernatants. It could be possible that the 
concentration of IgG antibody in unpurified hybridoma supernatant was low to begin with, 
leading to lack of visualisation of antibody in the IgG-enriched supernatants. 
 
A 1:100 dilution of each IgG-enriched hybridoma supernatant was chosen to evaluate its 
immunoreactivity against antigen because enriched supernatants were suspected to contain a 
lower concentration of primary antibody compared to commercial antibodies. Dilutions of 
each IgG-enriched hybridoma supernatant were prepared and probed against each 
cytoplasmic fraction (Figure 4.6). No immunoreactive bands were observed in fraction from 
non-transfected COS-7 cells, indicating that the enrichment process was successful in 
removing antibodies with activity against proteins endogenous to COS-7 cells. 
Immunoreactivity was observed for the cytoplasmic fraction of COS-7 cells transfected with 
hPXR, but not for the non-transfected COS-7 cells or those transfected with zfPXR. All five 
IgG-enriched hybridoma supernatants from cells of mice immunised with hPXR detected an 
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Figure 4.6. Immunochemical detection of IgG-enriched hybridoma supernatants. 
Western blot of 1 µg/mm of COS-7 cell cytoplasmic fractions on a PDVF membrane corresponding 
to: non-transfected COS-7 cells, cells transfected with hPXR, and cells transfected with zfPXR. 
Membranes cut into 3 mm strips and probed with purified hybridoma supernatants from either: cells 
immunised with hPXR (1:100) or from cells immunised with zfPXR (1:100). Non and hPXR 
transfected cells and were also probed with mouse anti-hPXR monoclonal IgG primary antibody 
(1:1000). All antibodies were detected with polyclonal goat anti-mouse IgG HRP-conjugated 
secondary antibodies (1:2000) and chemiluminescence was detected with the Amersham™ ECL™ 
Prime kit. 
 
 
immunoreactive protein corresponding to a size of approximately 50 kD, corresponding to 
what was detected by the commercial anti-hPXR antibody (Figure 4.3). In addition, two of 
these hybridoma supernatants, 5E4F9D9 and 8E2B8D7, also detected a second 
immunoreactive protein corresponding to a size of 55 kD, alongside with the anti-hPXR 
commercial body. 
 
4.1.4 Production and evaluation of the Histidine-tagged zfPXR test antigen in E. coli 
Because no commercial antibody current exists for zfPXR, it was not possible to verify that 
the cytoplasmic fraction of COS-7 cells transfected with zfPXR were producing sufficient 
amounts of test antigen, and immunoreactivity could not be detected using either the anti-
hPXR antibody or hybridoma supernatants. Therefore it was necessary to find another means 
of expressing zfPXR and effectively determining the presence of the protein before 
immunoprobing with hybridoma supernatants. In order to achieve this, a pET30b His-tagged 
zfPXR expression vector was used to transform E. coli Rosetta cells and an anti-histidine 
antibody was used to detect the expression of the resulting fusion protein (Methods 3.4). The 
expression of the fusion protein was induced by IPTG and degree of induction, as well as the 
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Figure 4.7. Evaluation of expression and solubility of the His-tagged zfPXR protein. 
Whole Rosetta cells from a 1 mL culture were adjusted so OD600 = 1.0, and corresponding amounts of 
soluble and insoluble fractions, were subjected to SDS-PAGE and proteins visualised by CBB 
staining. M represents 5 µL of the molecular weight standard; lane 1 represents E. coli Rosetta cells 
transformed with pET30b His-tagged zfPXR before induction; lane 2 represents cells post induction; 
lane 3 represents the soluble fraction of cells lysed after sonication; and lane 4 the insoluble fraction. 
 
 
solubility of the fusion protein was evaluated by SDS-PAGE (Figure 4.7). His-tagged zfPXR 
weighs approximately 55 kD (Saradhi et al., 2005), and proteins migrating to this size were 
observed for post-induced transformed Rosetta cells and in the insoluble fraction after lysis 
by sonication, but not in pre-induced cells or in the soluble fraction after sonication. This 
indicated that protein induction protein was successful and that the protein solubility was 
limited. 
 
Each of these samples alongside non-transformed E. coli Rosetta cells was also transferred to 
a PDVF membrane for immunodetection against a commercial anti-his primary antibody 
(Figure 4.8). For the non-transformed Rosetta cells and for the pre-induced transformed 
Rosetta cells transformed with pET30b His-tagged zfPXR no immunoreactivity was observed. 
However, immunoreactivity corresponding to a protein of a size of 55 kD was detected in the 
post-induced cells and in both the soluble and insoluble fraction of cells after sonication. The 
presence of immunoreactive ghost bands in the insoluble fraction indicate that the signal 
became saturated from an overloading of too much sample or that chemiluminescent 
substrate was being depleted too quickly. Because a high concentration of immunoreactive 
protein was observed in both SDS-PAGE and Western blotting, this component was used for 
subsequent analyses. 
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Figure 4.8. Immunological detection of histidine-tagged zebrafish Pxr expressed in E. 
coli Rosetta cells. Whole Rosetta cells from a 1 mL culture were adjusted so OD600 = 1.0, and 
corresponding amounts of soluble and insoluble fractions were transferred to a PDVF membrane. M 
represents 5 µL of the molecular weight standard; lane 1 represents non-transformed cells; lane 2 
represents cells transformed with pET30b His-tagged zfPXR before induction; lane 3 represents cells 
post induction; lane 4 represents the soluble fraction of lysed cells; and lane 5 the insoluble fraction. 
Membranes were probed with mouse anti-his IgG primary antibody (1:4000) and detected with a goat 
anti-mouse IgG HRP-conjugated secondary antibody (1:2000). Chemiluminescence was detected with 
the SuperSignal
®
 West Pico Chemilumiscent Substrate. 
 
 
 
Due to the sensitivity of the SuperSignal® West Pico Chemilumiscent Substrate, various dilutions 
of the insoluble fraction were run through a SDS-PA gel, transferred to a PDVF membrane 
and probed with anti-His primary antibody in order to determine the optimal ratio between 
antibody and the insoluble fraction containing the test antigen. The gel was also subjected to 
coomassie staining after Western blotting in order to determine the efficiency of protein 
transfer. Samples containing a higher concentration of the insoluble fraction failed to transfer 
protein from gel to PDVF as successfully as samples with a lower concentration (Figure 4.9). 
Samples diluted to 1:4 were still visible on an SDS-PA gel even after transfer. Despite this, 
the presence of a highly immunoreactive protein migrating to a size of 55 kD was confirmed 
immunochemically, in accordance to what was expected for His-tagged zfPXR within all the 
dilutions of the sample (Figure 4.10). It was concluded that the 1:8 dilution of the insoluble 
fraction of lysed E. coli Rosetta cells containing His-tagged zfPXR resulted in a sufficiently 
strong signal. This dilution was used to test the immunoreactivity of hybridoma supernatants. 
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Figure 4.9. Separation of protein in E. coli Rosetta cells by SDS-PAGE and evaluation 
of protein transfer during WB. Coosmassie stain of whole Rosetta cells from a 1 mL culture 
were adjusted so OD600 = 1.0, and corresponding dilutions of the insoluble fraction (100%, 3:4, 1:2, 
1:4, 1:8, 1:10 and 1:20 respectively) were run through SDS-PAGE before (A) and after (B) transfer to 
a PDVF membrane and visualised by CBB. M represents 5 µL of the molecular weight standard. A 
represents the separation of proteins within the insoluble fraction of transformed E. Coli Rosetta at 
different dilutions (100%, 3:4, 1:2, 1:4, 1:8, 1:10 and 1:20 respectively), alongside non-transformed 
cells. B represents the amount of visible protein visualised on an SDS-PA gel after transfer to a PDVF 
membrane. 
 
 
 
Figure 4.10. Immunochemical detection of His-tagged immunoreactive proteins in E. 
coli Rosetta cells. Whole Rosetta cells from a 1 mL culture were adjusted so OD600 = 1.0, and 
corresponding dilutions of the insoluble fraction (100%, 3:4, 1:2, 1:4, 1:8, 1:10 and 1:20 respectively)  
were transferred to a PDVF membrane. M represents 5 µL of the molecular weight standard; 
Membranes were probed with mouse anti-his IgG primary antibody (1:4000) and detected with a goat 
anti-mouse IgG HRP-conjugated secondary antibody (1:10000). Chemiluminescence was detected 
with the SuperSignal
®
 West Pico Chemilumiscent Substrate. 
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4.1.5 Immunoreactivity of zfPXR hybridoma supernatants 
Membranes containing the insoluble fraction from E. coli Rosetta cells expressing the His-
tagged zfPXR fusion protein were initially probed with each unpurified hybridoma 
supernatant in order to evaluate their immunoreactivity. However, no immunoreactive 
proteins corresponding a size of 55 kD were observed. Difficulties emerged in optimising the 
immunodetection of His-tagged zfPXR using the anti-His primary antibody as a positive 
control (data not shown), so IgG-enriched hybridoma supernatants were used instead to 
detect immunoreactivity (Figure 4.11). In cells expressing His-tagged zfPXR, the anti-His 
antibody detected an immunoreactive protein ranging from 55 to 50 kD and an additional 
protein at approximately 30 kD. No immunoreactivity was observed for the whole non-
transformed Rosetta cells or with the insoluble fraction containing His-tagged zfPXR. 
 
Figure 4.11. Immunochemical detection of IgG-enriched hybridoma supernatants. A 
Western blot of E. coli Rosetta cells corresponding to whole non-transformed cells and the insoluble 
fraction of lysed cells containing His-tagged zfPXR. A 1:40 dilution per mm of sample 
(corresponding to a 1:8 dilution per 5 mm well) was loaded into a 70 mm well and transferred to a 
PDVF membrane. Membranes cut into 3 mm strips and probed with purified hybridoma supernatants 
from mice immunised with zfPXR (1:50) and with mouse anti-His IgG primary antibody (1:4000) and 
detected with a goat anti-mouse IgG HRP-conjugated secondary antibody (1:10000). 
Chemiluminescence was detected with the SuperSignal
®
 West Pico Chemilumiscent Substrate. 
 
 
4.2 Zebrafish exposure experiment to clotrimazole 
Embryonic and adult zebrafish were initially set up in an exposure experiment to clotrimazole 
(Methods 3.7) in order to determine whether there pxr exhibited functional variation, by 
measuring expression levels of cyp3a65. This was not completed due to time restraints. 
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However, data was obtained on the number of individuals exposed, weights, sex and number 
of deaths (Table 4.2). 
 
The expression of cyp3a65 in zebrafish has been recently studied in embryos exposed up to 
10 μM of clotrimazole (Biancarosa, 2014), and so 40 adult zebrafish were initially exposed to 
10 µM clotrimazole in 0.25% DMSO for a planned period of 48 hours. However 100% 
lethality was observed after 3 hours. Thus the exposure concentration of clotrimazole was 
reduced to 1 µM (in 0.25% DMSO). For the embryo zebrafish exposure experiment, embryos 
exposed to 1 μM of clotrimazole, and no deaths were observed after 72 hours. 
 
Table 4.2. 
Data of adult zebrafish used in the exposure experiment with clotrimazole. 
Type of data Males Females Total 
Number survived 85 71 157
*
 
Deaths from 0.25% DMSO 0 0 0 
Deaths from 1 µM clotrimazole — — 3 
Deaths from 10 µM clotrimazole — — 40 
Weight (mg) 279 288 283† 
Average age (days) — — 525 
* The sex of one individual was not identified. 
† No significant difference was found in weight between sexes. 
 
 
4.3 RNA extraction and sequencing of pxr from individual zebrafish embryos 
Pxr from individual zebrafish embryos was sequenced in order to investigate genetic 
variation existed between individuals (see Figure 3.2 for experimental overview). The 
experimental strategy involved total RNA extraction from individual embryos, cDNA 
synthesis followed by PCR amplification of a select region of pxr for Sanger sequencing 
(Methods 3.8–9). Embryos were chosen because they were easy to obtain in large numbers 
and methods had been developed which allowed for total RNA extraction from individuals as 
young within the first few hours of fertilisation. Here, total RNA was extracted from 
individual embryos five days post fertilisation as part of an exposure experiment. 
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4.3.1 RNA extraction from zebrafish embryos 
Initially, attempts to extract total RNA from individual embryos essentially as described by 
de Jong et al. (2010) proved unsuccessful. Briefly, this method involved the homogenisation 
of individual embryos pre-chilled in liquid nitrogen, HPLG separation to physically separate 
RNA from DNA and protein, and cleanup to remove any residual DNA or contaminants 
present in the unpurified RNA extract (Methods 3.8.2). 
 
RNA extraction was first attempted with plastic pestles and QIAzol lysis reagent. In 
denaturing agarose gel electrophoresis, rRNA was clearly visible under UV light from RNA 
extracted from trout liver (at quantities as low as 50 ng), but absent in RNA extracted from 
individual embryos (Figure 4.12). This indicated that degradation was occurring in one of the 
three steps of the RNA extraction process, i.e. homogenisation, HPLG separation or cleanup. 
Plastic pestles were replaced with metal pestles and pre-chilled in liquid nitrogen before 
homogenisation and cleaned with 0.1% DEPC to minimise RNase activity, however samples 
lacked intact RNA (Figure 4.13). Eluate was also collected from each step of the cleanup 
process from two individuals and subjected through denaturing AGE (Figure 4.13). The 
cleanup involved two ethanol wash steps and one wash step with RPE buffer and eluates 
from each of these steps lacked intact rRNA compared to the non-degraded trout RNA, 
indicating that either: 1) RNA was already degraded before cleanup; or 2) RNA was being 
degraded in one or more steps during RNA cleanup. In addition, QIAzol lysis reagent was 
also replaced with TRI Reagent
®
 to test whether one lysis reagent performed better than 
another, however RNA degradation still occurred (data not shown). 
 
Figure 4.12. Evaluation of RNA quality by denaturing AGE. Total RNA was extracted from 
an individual zebrafish embryo homogenised with a plastic pestle and QIAzol lysis reagent. 200 ng of 
2-log DNA ladder was also loaded. 100 and 200 ng of sample were denatured in 50% formamide for 5 
min at 68 ºC, and subjected to denaturing AGE (1% agarose in TAE buffer at 35 min at 110 V). Pure 
trout RNA was loaded at different quantities (50, 100, 150 and 200 ng) and was used as a positive 
control to monitor degradation during the electrophoresis process. 
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Figure 4.13. Evaluation of RNA extraction from individual zebrafish embryos during 
RNA cleanup. Eluate from two individual zebrafish embryos was collected during each step of 
RNA cleanup using the RNA
®
 MinElute
TM 
Cleanup Kit. Total RNA was initially extracted using a 
pre-chilled metal pestle in liquid nitrogen and QIAzol lysis reagent. 100 ng of ladder, 4 µL of each 
wash eluate, and 100 ng final eluate and trout RNA (intact RNA control) were subjected to denaturing 
AGE. 
 
 
4.3.2 RNA extraction from adult zebrafish 
Total RNA was also extracted from adult livers using TRI Reagent
®
, both from two 
individuals and pooled samples of five and nine individuals (Methods 3.8.1, Figure 4.14). 
RNA was visualised in denaturing agarose gels under UV light. The yield of total RNA from 
the two individual embryos was calculated to be 25.8 and 68.8 µg and even higher for the 
pooled embryos—253 and 415 µg respectively (Table 4.2). These values suggested that it 
was possible to obtain a high yield of RNA from individual adult livers and that pooling of 
samples increased the quantity of RNA obtained. For all samples, the A260/280 ratio always 
exceeded 1.80. Total RNA from a single individual was then used as a positive control for 
subsequent denaturing gels as well as a means to quantify RNA degradation in the RNA 
cleanup process used for extracting RNA from individual zebrafish embryos. 
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Figure 4.14. Evaluation of RNA quality by denaturing AGE. Total RNA from the liver of 
zebrafish adults was obtained from two individuals and two pools of five and nine individuals using 
the TRI Reagent protocol. 200 ng of 2-log DNA ladder, sample and trout liver RNA were subjected to 
denaturing AGE. Lanes 1–2 represent RNA obtained from individual livers (n=1) and lanes 3 and 4 
represent five livers (n = 5) and nine livers (n = 9) respectively. 
 
 
Table 4.2 Yield and integrity of total RNA obtained from liver of zebrafish adults. 
Total RNA from the liver of zebrafish adults obtained from two individuals and two pools of five and 
nine individuals using the TRI Reagent protocol. RNA was extracted using the TRI Reagent protocol 
and collected in 100 µL of RNase-free water. Concentrations were calculated using a NanoDrop
®
 ND-
1000 spectrophotometer. 
Number of livers Concentration (ng/µL) Total RNA (µg) A260/280 
1 258 26 1.80 
1 688 69 1.84 
5 2526 253 1.88 
9 4148 415 1.88 
 
 
4.3.3 Optimisation of an RNA extraction method from zebrafish embryos 
After determining it was possible to extract total RNA from individual adult livers, different 
quantities of zebrafish liver total RNA from a single individual were subjected through the 
HPLG separation and RNA cleanup steps in order to determine if RNA was being degraded 
before or during purification (Methods 3.8.2–3). Quantities of 4000, 2000, 1000 and 500 ng 
of RNA were prepared to determine whether final yield would vary depending on the initial 
amount of RNA loaded. However, denaturing AGE demonstrated that RNA was degraded 
during cleanup, so attention was directed towards optimising this procedure to remove any 
sources of degradation. 
 
Wash solutions used in the RNA
®
 MinElute
TM 
Cleanup Kit were replaced, and different 
quantities of zebrafish liver total RNA (4000, 2000, 1000 and 500 ng) from a single 
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individual were subjected through RNA cleanup a second time, followed denaturing AGE 
(Methods 3.8.4, Figures 4.15). This time intact RNA was obtained, indicating that one of the 
wash solutions was responsible for RNA degradation and that RNase contamination had 
occurred. The final yield of RNA obtained from each input was measured using the 
NanoDrop
®
 ND-1000 spectrophotometer (Table 4.3), and it was found that at least 37% of 
the RNA subjected through the cleanup process was retained. When 500 ng of RNA was 
subjected through cleanup, however, a recovery greater than the input was observed, and this 
could have been due to pipetting errors or uncertainties in quantifying RNA concentrations 
(see Discussion). 10 pg to 1 µg of total RNA is recommended for cDNA synthesis 
(depending on how much of the copy gene of interest is present in the sample), so 1000 ng of 
initial total RNA yield from an individual embryo was deemed sufficient for cDNA synthesis. 
Extraction of total RNA from individual embryos was therefore continued using metal pestles 
pre-chilled in liquid nitrogen, TRI Reagent (although QIAzol lysis reagent could have been 
used), HPLG separation and the RNA
®
 MinElute
TM 
Cleanup Kit. 
 
 
Figure 4.15. Evaluation of total RNA recovered from RNA cleanup. Total RNA obtained 
from the liver of zebrafish adults was subjected through RNA cleanup using the RNA
®
 MinElute
TM 
Cleanup Kit. Different quantities adult liver RNA (4000 ng, 2000 ng, 1000 ng and 500 ng) were 
loaded through the cleanup process and collected in eluate. 100 ng of 2-log DNA ladder, eluate from 
each loading and zebrafish liver RNA (intact positive control) was subjected to denaturing AGE. 
 
Table 4.3. Recovery of total RNA subjected through RNA cleanup. 
Yield and recovery of total RNA from zebrafish liver of a single individual subjected through RNA 
cleanup using the RNA
®
 MinElute
TM 
Cleanup Kit. Concentration was calculated using a NanoDrop
®
 
ND-1000 spectrophotometer and yields were calculated from 14 µL of final eluate. 
Input of RNA (ng) Yield of RNA (ng)  Recovery A260/280 ratio 
4000 2230 56% 1.98 
2000 748 37% 1.80 
1000 577 58% 1.74 
500 666 100% 1.58 
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4.3.4 Comparison of total RNA extraction methods from zebrafish embryos 
After demonstrating that it was possible to obtain intact RNA from individual adult zebrafish 
livers using TRI Reagent
®
, this lysis reagent was used for the remainder of RNA extractions. 
In addition to the extraction total RNA from individual embryos using HPLG separation and 
RNA cleanup, total RNA was also extracted from embryos using the TRI Reagent protocol as 
carried out with adult livers (Figure 4.16 & Table 4.4). Total RNA was extracted from 
individuals as well as from pools of five and ten individual embryos. In all cases of RNA 
extraction using HPLG separation, it was possible to obtain total RNA concentration from 
each sample with yields greater than 1.4 µg. For pooled individuals however, RNA yield was 
higher in the pooled sample of five compared to ten embryos. The A260/280 ratio in each 
sample was also greater than 1.90.  
 
Extraction of total RNA using the TRI Reagent protocol led to mixed results (Figure 4.16 & 
Table 4.4). Total RNA extracted from three individuals indicated that RNA had degraded, 
due to the absence of 28S and 18S rRNA visualised under UV light. Only the extraction of 
total RNA from a single individual was successful. Extraction of RNA from individual 
zebrafish embryos using the TRI Reagent protocol was difficult and likely requires further 
technical optimisation to minimise the effect of RNA degradation.  Extraction of RNA from 
five embryos gave a higher yield, but lacked intact rRNA after denaturing AGE. The pool of 
ten embryos gave a lower yield but contained intact rRNA after denaturing AGE. Caution 
should be taken when assessing RNA quality according to its yield, purity and rRNA. 
 
Figure 4.16. Evaluation of RNA quality extracted using HPLG separation and the TRI 
Reagent protocol. Total RNA from zebrafish embryos was obtained using both HPLG separation 
and the TRI Reagent protocol. Lanes 1–4 used HPLG separation to obtain RNA (lanes 1–2 from 
individual embryos and lanes 3–4 from pools of five and ten individuals). Lanes 5–10 used the TRI 
Reagent protocol to obtain RNA (lanes 5–8 from individual embryos and lanes 9–10 from pools of 
five and ten individuals). 200 ng of 2-log DNA ladder, sample and trout liver RNA were subjected to 
denaturing AGE. 
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Table 4.4. Yield and purity of total RNA obtained from liver of zebrafish adults. 
Yield and A260/280 ratios of total RNA extracted from individual and pooled embryos using both HPLG 
separation and TRI Reagent. Yield was calculated using a NanoDrop
®
 ND-1000 spectrophotometer. 
Total RNA extracted from embryos using HPLG separation was eluted in 14 µL of RNase-free water 
and 20 µL of RNase-free water for RNA extracted using the TRI Reagent. 
RNA extraction method Number of 
individuals used  
Yield (µg) A260/280 
ratio 
HPLG separation 1 1.6 1.90 
HPLG separation 1 1.4 1.95 
HPLG separation 5 13.9 1.98 
HPLG separation 10 4.8 1.97 
TRI Reagent 1 1.0 1.69 
TRI Reagent 1 3.4 1.70 
TRI Reagent 1 0.5 1.69 
TRI Reagent 1 1.1 1.88 
TRI Reagent 5 16.4 1.46 
TRI Reagent 10 8.7 1.67 
 
 
Extraction of total RNA from individual zebrafish embryos using HPLG separation was then 
scaled up to 24 individuals (Figure 4.17). The average yield of RNA extracted from 
individual embryos was 1969 ± 578 ng (Table A3, Appendix A). A260/280 ratio was always 
greater than 1.80 (1.90 ± 0.06), except for two of the samples, suggesting that RNA was 
generally of high purity. Therefore, cDNA synthesis was continued with all samples, even 
when rRNA was difficult to visualise on denaturing agarose gel. 
 
 
Figure 4.17. Evaluation of RNA quality by denaturing AGE. Total RNA was extracted from 
24 individual embryos using HPLG separation and RNA cleanup. 200 ng of 2-log DNA ladder and 
each sample were subjected to denaturing AGE. 
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4.3.5 PCR amplification of zebrafish pxr 
4.3.5.1 cDNA synthesis and control of cDNA quality 
Complementary DNA was synthesised from 500 ng of RNA using the qScript
TM
 cDNA 
Synthesis Kit (Methods 3.9.1). The quality of the cDNA was evaluated by amplification of 
the high copy gene beta-actin using the cDNA as template (Methods 3.8.2). As expected, a 
product of approximately 500 bp was amplified from all cDNA synthesised (Figure 4.18), 
indicating that mRNA within each sample of total RNA had been successfully reverse 
transcribed into cDNA. 
 
 
Figure 4.18. Evaluation of the beta-actin PCR product. cDNA from 24 individuals was 
amplified with primers flanking the zebrafish beta-actin gene. 250 ng of 2-log DNA ladder and 3 µL 
of each sample were subjected to AGE (1% agarose in 1 × TAE at 35 min at 110 V). The negative 
control represents a PCR reaction that did not contain a cDNA template. 
 
4.3.5.2 Amplification of full length zebrafish pxr 
The full open reading frame of the zebrafish pxr gene was amplified by PCR using the cDNA 
previously synthesised as a template (Methods 3.9.2). As expected the amplification product 
was approximately 1.3 kb in size (Figure 4.19). 
 
Figure 4.19. Evaluation of the full length zebrafish pxr PCR product. cDNA from 24 
individuals was amplified with primers flanking the zebrafish pxr gene. 250 ng of 2-log DNA ladder 
and 3 µL of each sample were subjected to AGE. 20 ng of pcDNA vector containing zebrafish pxr 
was also amplified and 3 µL was used as a positive control. The negative control represents a PCR 
product which did not contain a cDNA template. 
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Following amplification, the total reaction volume of each PCR product (47 µL) was run 
through PCR cleanup using GenElute
TM
 PCR Clean-Up Kit and subjected to AGE (Figure 
4.20). The average yield of PCR product obtained from each sample after cleanup was 783 ± 
82 ng (Table A4, Appendix A). The size of the product (approximately 1.3 kb) was consistent 
with the product before cleanup. 
 
 
Figure 4.20. Evaluation of the full length zebrafish pxr PCR product after cleanup. PCR 
product of full length zebrafish pxr from 24 individuals after PCR cleanup. 100 ng of 2-log DNA 
ladder and each sample were subjected to AGE. 
 
 
4.3.6 Sequencing of zebrafish pxr 
40 ng of each purified PCR product was used a template for Sanger sequencing (Methods 
3.9.3). A forward and reverse primer were selected to sequence the full open reading frame of 
the zebrafish pxr gene from nucleotides 478 to 1070, as this region includes two codons 
known to contain allelic variation. Contigs were created from forward and reverse sequences 
from each individual, translated and aligned using ClustalW. Consensus sequences 
representative of a section of pxr from each individual were compared with one another, 
however all 24 individuals contained identical sequences. The chromatogram, which contains 
specific peaks for each ddNTP along a stretch of a sequence, was also checked briefly to 
determine if any sequencing errors were present. Some individuals exhibited what appeared 
to be heterozygous peaks at some nucleotides of the pxr sequence, which could suggest that 
SNPs exist at these loci (Figure 4.21). Interpretations of findings made from the 
chromatograms are detailed in the Discussion. 
 
The zfPXR sequence representative of all 24 individuals was also aligned with amino acids 
180 to 338 of two zfPXR sequences from UniProtKB (identifiers: A5WYG8/unknown and 
F1R424/Tu)  to determine whether there was any genetic variation (Figure 4.22). These 
online sequences corresponded to an unknown strain and Tu zebrafish. Five non-synonymous 
substitutions and one amino acid insertion were found and these substitutions corresponded  
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Figure 4.21. Chromatogram comparison in a region of zebrafish pxr between two 
individuals. Chromatogram (A) contains no overlapping base pair peaks; whereas chromatogram 
(B) contains several overlapping peaks which could represent the sequencing of a heterozygous gene 
(indicated below the main sequence. 
 
 
to: substitutions L186V, M202V, P208S, N232S and S234T; and insertion N223. These 
substitutions corresponded to all the major (i.e. found in three or more individuals) variant 
residues found in pxr*1 of TL zebrafish as described by Bainy et al. (2013), but to none in 
pxr*2 of TL (containing allelic variants I184S and C218Y). This means that pxr sequence 
obtained from the 24 zebrafish embryos corresponds to the pxr*1 allele. The Tu strain found 
online however did contain a sequence which corresponded to the pxr*2 allele in the TL 
strain. 
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Figure 4.22. Multiple sequence alignment of zebrafish pxr variants and orthologs. Amino 
acid sequence alignment of AB/Tu strain zebrafish pxr from this study compared to an unknown 
strain (Unk) and the Tu strain of zebrafish from UniProtKB/TrEMBL (identifiers: A5WYG8/Unk and 
F1R424/Tu). The zebrafish pxr sequences were also compared to human PXR and mouse Pxr 
(UniProtKB/Swiss-Prot, identifiers: O75469/human and O54915/mouse). The secondary structure 
represents the hPXR LBD interacting with rifampicin (PDB Id: 1SKX). Sequences were aligned using 
Clustal Omega and visualised in Jalview (v2.8.0b1). Residues known to contain allelic variants in the 
TL strain by Bainy et al. (2013) are indicated by an asterisk; differences between AB/Tu and both the 
Unk and Tu strain are indicated by a caret. 
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5. Discussion 
 
This study has focused on PXR, a nuclear receptor which regulates the transcription of genes 
for enzymes involved in the biotransformation of endogenous and xenobiotic compounds. 
Ligands for PXR include a wide range of steroids, natural products as well as pollutants. 
Understanding how a particular compound can activate PXR to induce gene expression is 
especially important from both an ecotoxicological and pharmacological perspective, and 
studies on this can be used to expand our knowledge on PXR function. 
 
Studies on PXR can be achieved both in vitro and in vivo. Such studies can be used to help 
form the basis of risk assessment and decision making (Sheldon and Hubal, 2009), especially 
when considering compounds that interact with this nuclear receptor. Furthering our 
understanding of PXR function can help researchers draw more detailed conclusions when 
choosing appropriate animal species to use and compare to in toxicological testing. 
 
In this study, we aimed to validate monoclonal antibodies against human and zebrafish PXRs 
due to the fact that commercial antibodies specific against this nuclear receptor are either 
limited (in the case of zfPXR, no commercial antibody exists) and/or generally polyclonal, i.e. 
antibodies bind to multiple epitopes of the same antigen. Hybridoma cells developed from 
mice immunised either with human PXR or zebrafish Pxr had been developed in a previous 
Master’s project (Davies, 2011). Here, we further characterised these hybridomas by 
recombinant antigen expression and enrichment of the IgG fraction from the hybridoma 
supernatants. Monoclonal antibodies from cells of mice immunised with hPXR demonstrated 
good specificity to its antigen, whereas those from mice immunised with zfPXR detected no 
immunoreactivity against the denatured zfPXR antigen. 
 
Another aspect of this study was to identify pxr variants in zebrafish embryos. Zebrafish are 
an extensively studied organism whose relevance in toxicology makes them a useful model 
species for studying response to newly discovered drugs, as well as to pollutants in the 
aquatic environment (Coe et al., 2009; Rubinstein, 2006; Barros et al., 2008). However, 
information about pxr in this species is limited, at least compared to what has been 
investigated in humans. This study focused on a region of pxr previously identified to contain 
genetic variation in the TL strain (Bainy et al., 2013). RNA was extracted from individual 
embryos belonging to the AB/Tu strain and pxr was sequenced from 24 individuals. None of 
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the individuals exhibited genetic variation compared to those from TL strain, but amino acid 
differences were identified when compared to a sequence of the gene available in GenBank. 
 
5.1 Immunoreactivity of hybridoma supernatants 
For all IgG-enriched hybridoma supernatants from cells of mice immunised with hPXR, an 
immunoreactive protein was detected corresponding to an expected size of 50 kD when tested 
against the cytoplasmic fraction of COS-7 cells transiently expressing hPXR (Figure 4.6). 
However, two of the supernatants, 5E4F9D9 and 8E2B8D7, also unexpectedly detected an 
immunoreactive protein corresponding to a size of approximately 55 kD. The presence of this 
additional protein could be due to a number of reasons and is discussed in further detail in the 
following section. 
 
5.1.1 Multiple isoforms of PXR 
Splice variation refers to when the exons of a gene are spliced alternatively into an mRNA 
sequence. This can lead to gene variants possessing fewer exons than the original genomic 
sequence and thus different protein isoforms after translation (Venter et al., 2001). For 
nuclear receptors, alternative splicing can lead to different levels of target gene expression, 
protein interaction and subcellular localisation (Keightley, 1998). In humans, seven splice 
variants or isoforms have been identified in PXR (Table 3.1), and some of these isoforms 
have been shown to have differing levels of ligand activation and target gene expression 
(Gardner-Stephen et al., 2004; Fukuen et al., 2002). PXR isoforms have also been identified 
in pigs (Pollock et al., 2007). 
 
In humans, isoform 1, consisting of 434 amino acids with an calculated molecular weight of 
50 kD (Table 5.1), is referred to as “canonical” because it is the most functional and 
commonly occurring isoform in humans  (Lamba et al., 2004; Gardner-Stephen et al., 2004). 
Isoform 3 contains an additional 39 amino acids, making it 473 amino acids long and 
approximately 54 kD. This isoform coincides to the second immunoreactive protein detected 
by two of the hybridoma supernatants and the commercial anti-hPXR antibody. 
 
The detection of a second, heavier immunoreactive protein was also observed by Saradhi et 
al. (2005), where the immunoreactivity of polyclonal anti-hPXR antibodies from antiserum 
was tested against lysed COS-1 cells transfected with hPXR. Immunoreactive protein 
detected at 50 kD was observed in the COS-1 cell lysate, as well as an additional protein at 
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55 kD. The study suggested that the detection of additional immunoreactive proteins as well 
as the expected one detected at 50 kD could correspond to isoforms of PXR. Saradhi and co-
authors refer to a study where the glucocorticoid receptor (GR, NR3C1), another type of 
nuclear receptor, was expressed in COS-1 cells and detected using an anti-GR antibody (Lu 
and Cidlowski, 2005). They conclude that the immunodetection of paralogous GR isoforms 
could help explain their own findings, but failed to acknowledge that the COS-1 cells were 
transfected with expression vectors coding for multiple isoforms of GR, rather than for a 
single isoform. Alternative splicing of recombinant DNA does not occur during transient 
transfection (unless the recombinant DNA also contains introns which is uncommon), 
indicating that the recombinant gene within pDNA is always translated into the same mRNA 
sequence and always transcribed to same final protein. This means that the appearance of 
multiple immunoreactive proteins observed in our study do not correspond to different 
isoforms of PXR as a result of alternative splicing of the gene located on the recombinant 
DNA. 
 
Table 5.1 
Isoforms of human PXR and their respective differences between one another. 
Isoform UniProtKB/Swiss-
Prot identifier 
Amino acid 
differences 
Amino 
acids 
Size (kD) 
1A O75469-1 Canonical 434 50 
1B O75469-2 Missing 1–55 379 44 
1C O75469-3 Additional 24  457 52 
2A O75469-4 Missing 174–210 397 46 
2B O75469-5 Missing 1–55 
Missing 174–210 
342 40 
2C O75469-6 Additional 24  
Missing 174–210 
420 48 
3 O75469-7 Additional 39  473 54 
 
 
5.1.2 Post-translational modification of PXR 
Another explanation for the appearance of this heavier immunoreactive protein is that hPXR 
has undergone a post-translational modification. PXR has been demonstrated to undergo 
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different forms of post-translational modifications, including phosphorylation, SUMOylation, 
ubiquitination and acetylation (reviewed in Smutny et al., 2013; Staudinger et al., 2011). 
Post-translational modifications are also found in other nuclear receptors and are an important 
part of cell regulation (Rochette-Egly, 2003). For antigen probed with the commercial anti-
hPXR antibody, it is interesting to note that the immunoreactivity of the protein is greater at 
50 kD than 55 kD, suggesting that if post-translated PXR is being detected, it exists at a much 
lower concentration than its unmodified counterpart when expressed in COS-7 cells.  
 
Alternatively, supernatants might have been reacting against an epitope of the protein which 
contained a modified site. Depending on the type of modification, it could be possible that 
this leads to a reduction or loss of binding towards antibodies in the supernatant (Jeltsch, 
2013). One way of confirming the post-translational modification of PXR would have been to 
test the immunoreactivity of prokaryotically expressed hPXR towards a commercial antibody. 
This is because in prokaryotic systems, post-translational protein modifications occur less 
frequently than in eukaryotic expression systems (Walsh and Jefferis, 2006). 
 
5.1.3 Cross-reactivity of anti-hPXR against PXR orthologs 
In theory, it is possible that the COS-7 lysates contained endogenous isoforms of monkey 
PXR which were cross-reactive with the commercial anti-hPXR antibody. The commercial 
anti-hPXR antibody used in this study is reported to be specific to all isoforms of hPXR 
except those lacking the first 55 amino acids, i.e. isoform 1B and 2B (R&D systems). The 
antibody was prepared by immunising mice with a recombinant form of the human PXR 
isoform 1 containing the first 40 amino acids of the open reading frame of the sequence. It 
was not stated whether the anti-hPXR antibody was cross-reactive with closely related PXR 
orthologs. However, a comparison of the 40 amino acid sequence of hPXR with other species 
will indicate whether such cross-reactivity is likely to occur. 
 
The sequence for Green monkey PXR has yet to be determined. However, PXR has been 
cloned and sequenced in Cynomolgus and Rhesus monkeys and shown to be highly 
homologous to human PXR (96%) (Kim et al., 2010). Given these two species along with the 
Green monkey belong to same clade, family Cercopithecidae, the possibility of Green 
monkey PXR containing the same degree of similarity to human PXR is highly likely. In the 
study by Kim et al. (2010), the first 40 amino acids of the two monkey PXR sequence 
compared to hPXR varies only by five amino acids (Figure 5.1). 
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Figure 5.1. Sequence differences in the first 40 amino acids between PXR in human and the 
Cynomolgus monkey, Rhesus monkey and zebrafish. Figure adapted from Kim et al. (2010). 
 
 
A minimum of fifteen amino acids residues of the epitope are required when binding with an 
antibody (Frank, 2002). Of these fifteen residues, only five strongly influence the antibody’s 
binding affinity towards the epitope (Benjamin and Perdue, 1996). In theory, it could then be 
possible for anti-hPXR to be cross-reactive with monkey PXR, given that the exact location 
of the epitope lies within a conserved region of the sequence of the first 40 amino acids. The 
only way to confirm this would be through the immunochemical detection of the monkey 
PXR antigen towards the commercial antibody. In the case of zfPXR, the first 40 amino acids 
of the sequence resemble little similarity to its human counterpart, meaning that an anti-
hPXR antibody targeting an epitope in this region is highly unlikely to cross-react with a 
zfPXR antigen. 
 
Human PXR is expressed in low levels in the kidney (Nishimura et al., 2004), and this could 
reflect what occurs in non-transfected COS-7 cells (Figure 4.6), since these originate from the 
kidney tissue of the Green monkey. Thus the absence of immunoreactive protein detected in 
non-transfected cells could have been due to: 1) endogenous PXR not being expressed; 2) 
endogenous PXR being expressed at levels too low for immunodetection; 3) anti-hPXR 
antibody not being cross-reactive with monkey PXR. 
 
5.1.4 Cross-reactivity of anti-hPXR against closely related nuclear receptors 
The nuclear receptors CAR and VDR are most closely related to PXR, and have been shown 
to be expressed at high levels in the human kidney (Nishimura et al., 2004). This means that 
COS-7 cells could also contain higher levels of these proteins compared to endogenous PXR. 
As a result, hybridoma supernatants from cells of mice immunised with hPXR could also 
potentially be immunoreactive against monkey CAR and monkey VDR. 
 
As discussed, the epitope of an antibody generally needs to be highly conserved for cross-
reactivity to occur. For the anti-hPXR antibody, the epitope was located in the first 40 amino 
acids of the sequence, corresponding to a poorly conserved region between different nuclear 
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receptors (reviewed in Pawlak et al., 2012). Therefore it is highly unlike that the commercial 
anti-hPXR antibody cross-reacted with endogenous CAR and VDR. 
 
5.1.5 Epitope of antibodies from hybridoma supernatants 
5.1.5.1 Antibodies specific against unexpected epitopes 
No immunoreactivity was detected in the three hybridoma supernatants from cells immunised 
with zfPXR when tested against COS-7 cells transfected with zfPXR or against the insoluble 
fraction of lysed Rosetta cells containing His-tagged zfPXR (Figure 4.11). This is in contrast 
to findings made by Davies (2011), whereby three hybridoma supernatants from cells 
immunised with zfPXR detected an immunoreactive protein corresponding to a 
prokaryotically expressed His-tagged zfPXR antigen (Figure B1, Appendix B). In addition, 
Davies was also able to demonstrate cross-reactivity of these supernatants against an hPXR 
antigen. 
 
It could be possible that hybridoma supernatants from cells immunised with zfPXR were only 
immunoreactive to the histidine tag fused to the Pxr protein. In Davies’ study, mice were 
immunised to His-tagged zfPXR. This antigen was developed in a previous Master’s project 
whereby His-tagged zfPXR was transformed in a prokaryotic cell line, expressed with IPTG 
and purified using a Ni-NTA column that binds to His-tagged proteins (Mork-Jannson, 2010). 
Given that the monoclonal antibodies in mice were generated in response to the His-tag itself, 
then it is possible that these would be immunoreactive against any recombinant protein fused 
with this tag. This could be confirmed by immunochemically determining whether the 
hybridoma supernatants respond against a His-tag protein not related to PXR. Interestingly, 
Davies detected immunoreactivity in most hybridoma supernatants against both His-tagged 
zfPXR and His-tagged hPXR. This could explain why no immunoreactivity was observed for 
COS-7 cells transfected with untagged zfPXR (Figure 4.6), but does not explain a lack of 
immunoreactivity detected against the Rosetta cells which contained His-tagged zfPXR 
(Figure 4.11). 
 
5.1.5.2 The specificity of monoclonal antibodies 
The production of hybridoma clones by limiting dilution does not always yield antibodies 
which are monospecific in nature (Underwood and Bean, 1988). When selecting hybridoma 
clones containing monoclonal antibodies, often the most reactive hybridoma cultures are 
chosen instead of those which are the most specific (Staszewski, 1984). It could be possible 
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that the most reactive hybridoma cultures initially selected were more reactive because they 
contained a higher level of cross-reactivity as opposed to mono-reactivity against the desired 
antigen. It is possible that some of the antibodies generated by the hybridomas from cells 
immunised with zfPXR may not have been monospecific. 
 
For this reason, it could be argued that some of these antibodies may have only been 
immunoreactive against zfPXR in a conformational state. The initial expression of zfPXR by 
prokaryotic cells to be used for immunisation could have resulted in the production of 
antibodies which were only immunoreactive against a conformational epitope as a result of 
protein folding or misfolding, which is common for eukaryotic proteins expressed in 
prokaryotes. This could explain why no immunoreactivity was observed between hybridoma 
supernatants from cells of mice immunised with zfPXR and the zfPXR antigen probed in its 
linear, denatured state. In order to determine whether the epitope of these antibodies is 
conformational, the incorrectly folded proteins could be subjected to immunodetection 
towards the hybridoma supernatants with the omission of a heat denaturation step. 
 
5.1.6 Proteasomal degradation of the test antigen 
When testing the immunoreactivity of the commercial anti-His antibody against the lysed 
Rosetta cells containing His-tagged zfPXR, protein was detected ranging from 55 to 50 kD 
and approximately 30 kD (Figure 4.11). Initial attempts to optimise the immunodetection of 
the His-tagged positive control proved challenging, and this additional, lighter 
immunoreactive protein was present in many of these initial tests. 
 
It could be possible that His-tagged zfPXR undergoes proteasomal degradation in prokaryotic 
cells despite the inclusion of protease inhibitors before and after cell lysis. In the case of 
degradation, it could have been problematic for hybridoma supernatants to cross-react with 
His-tagged zfPXR if there was antigen degradation to begin with. Moreover, if the epitope 
was retained in a partially degraded protein, this could explain the detection of 
immunoreactive proteins corresponding to a smaller size than expected. Protein degradation 
has also been suggested to occur for COS-1 cells transfected with zfPXR (Saradhi et al., 
2005), suggesting that cleavage of the protein could occur. Studies have shown that the 
stability and solubility of the PXR LBD in E. coli cells is poor and subject to degradation 
(Jones et al., 2002; Wang et al., 2008). This is because incorrect folding of the protein makes 
proteins more susceptible to degradation. Stability was improved however after cells were 
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coexpressed with a fragment of the nuclear receptor coactivator, steroid receptor coactivator 
1 (SRC-1), a protein which assists in the transcriptional activity of PXR (Wang et al., 2008). 
Since the stability of full length PXR tethered to SRC-1 has not yet been tested, then the 
coexpression of the PXR LBD with SRC-1 could have been considered in study, given that 
the epitope of the hybridoma supernatants are immunoreactive against the LBD.  
 
5.1.7 Improvement of immunodetection by IgG enrichment 
One of the unpurified hybridoma supernatants from cells immunised with hPXR, 5E4F9D9, 
was immunoreactive against a protein of a size of 55 kD in both non-transfected COS-7 cells 
and with COS-7 cells transfected with hPXR, indicating that the supernatant could react 
against COS-7 specific proteins. This apparent non-PXR specific immunoreactivity was also 
observed by Davies (2011). However, after IgG enrichment of the supernatant, the non-
specificity was removed against the non-transfected cells, while reactivity against a 55 kDa 
protein in COS-7 cells expressing hPXR was retained. This indicates that IgG enrichment 
increase the specificity of the supernatants. In addition, Davies was unable to detect 
immunoreactivity of the unpurified hybridoma supernatant 12D5B5C8 against eukaryotically 
and prokaryotically expressed hPXR. However, in this study we were able to demonstrate 
that it was in fact possible to detect the immunoreactivity of this supernatant, but only after 
IgG enrichment.  
 
These findings demonstrate that IgG enrichment of the hybridoma supernatants is a useful 
step. However, when IgG-enriched hybridoma supernatants were subjected to SDS-PAGE 
and visualised using CBB, proteins corresponding to the light and heavy chains of the 
antibody could not be detected (Figure 4.5). The absence of the light chain suggests that the 
amount of antibody subjected to SDS-PAGE was too low to be detected by staining, and this 
could be attributed to the fact that the light chain band was much weaker than the heavy chain 
band in the unpurified hybridoma supernatants also. Because destaining of SDS-PA gels 
depends on the sample loaded with the highest quantity of protein loaded (in this case the 
unpurified supernatant), it could be possible that CBB staining the light chains (in the IgG-
enriched samples) was removed. Rerunning SDS-PAGE with a lower quantity of unpurified 
hybridoma supernatant and a higher quantity of IgG-enriched supernatant might improve this. 
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5.1.8 Subcellular localisation of PXR orthologs 
As discussed previously, the subcellular localisation of PXR is a disputed topic (reviewed in 
Zhou et al., 2009). In mice, endogenous PXR has been show to be localised exclusively in the 
nucleus in the presence and absence of a ligand such as PCN (Saradhi et al., 2005). On the 
contrary, research has also demonstrated endogenous PXR in mice is localised in the 
cytoplasm prior to treatment with the PCN ligand (Squires et al., 2004). 
 
The ambiguity in the subcellular localisation of PXR before and after ligand treatment meant 
that it was an important step to fractionate both the cytoplasmic and nuclear fractions of 
COS-7 cells in order to determine where immunoreactivity was occurring. However, addition, 
it was not practical to compare studies between the localisation of endogenous and 
recombinant expressed PXR. In this study we demonstrated that for hPXR, localisation 
occurred both in the cytoplasm and nucleus of transfected COS-7 cells 24 hours after 
treatment with rifampicin, with the greatest immunoreactivity being detected in the cytoplasm 
(Figure 4.3). This contradicts findings made by Koyano et al. (2004), where they 
demonstrated that localisation in COS-7 cells transfected with hPXR occurred in the nucleus 
48 hours after transfection and 24 hours after ligand treatment (vehicle control or rifampicin). 
However the negative control used in this study differs to the one used by Koyano and co-
authors in three ways: 1) negative control COS-7 cells in this study were not transfected with 
hPXR; 2) non-transfected cells were not treated with either ligand or a vehicle control; and 3) 
localisation was determined by cellular fractionation and Western blotting (as opposed to 
immunocytochemistry of whole cells). The differences in the immunodetection of the 
subcellular localisation of PXR warrants further investigation and could form the basis of 
testing variation in immunoreactivity according to design and methodology. 
 
It could also be possible that the localisation of recombinant PXR differs between COS-7 
cells transfected with either hPXR and zfPXR. One possibility for the lack of 
immunoreactivity detected for COS-7 cells transfected with zfPXR is that the antigen could 
have translocated to the nucleus after treatment with clotrimazole, and these fractions were 
not used for subsequent analyses. Future studies could investigate PXR localisation in COS-7 
cells by transfection of cloned PXR orthologs which have antibodies developed towards them 
(e.g. human, rodent, rabbit). Another option could be to tag recombinantly expressed PXR 
with protein tags such as green fluorescent protein (GFP, a protein which fluoresces when 
exposed to blue light), if antibodies specific to the nuclear receptor do not exist.
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5.2 RNA extraction for sequence analysis 
The extraction of total RNA from individual embryos proved difficult, due to degradation of 
genetic material. However, after the removal potential RNase contaminants, it was possible to 
extract total RNA from individuals with a high degree of success. The following section 
discusses how particular methods used in this process aided in the extraction of genetic 
material in both high quality and quantity. 
 
5.2.1 Importance of homogenisation method 
Obtaining total RNA from individual zebrafish embryos using the TRIzol Reagent protocol 
was challenging due to the embryo’s small size, however a high quantity of RNA was 
obtained after the pooling of five and ten individual embryos. For many studies where the 
availability of biological sample is limited, a pooling of samples is often necessary (Linney et 
al., 2004). This becomes impractical however when investigating sequences or gene 
expression levels resulting from individual variation (Jolly et al., 2005; Mary-Huard et al., 
2007). On the other hand, pooling might be necessary when overall gene expression is more 
important than individual variation, and care should be taken in deciding whether analysing 
embryos individually or in pools is more important. 
 
In this study, we were interested in identifying genetic variation in pxr between individuals, 
meaning that sequencing pooled samples would not have given us the results we were 
looking for. Various methods for extracting total RNA from individuals were evaluated in 
this study, including: choice of pestle, lysis reagent, phase separation and column purification. 
 
5.2.2 Evaluation of total RNA extraction methods from individual zebrafish embryos 
5.2.2.1 Facilitation of RNA extraction by pestle type 
Zebrafish embryos possess a rubbery epidermis making it challenging to homogenise 
individuals completely. The use of plastic pestles to homogenise individual embryos proved 
unsuccessful. Therefore it was necessary to pre-chill embryos in liquid nitrogen and then 
crush individuals using a metal pestle pre-chilled in the same liquid. Crushing embryos in this 
manner allowed for the homogenisation of the sample into a fine powder, which helped 
facilitate RNA extraction and reduce RNA degradation. Similar methods have been 
developed for skin biopsies, which are tough and rich in RNases (Bruning et al., 2011). The 
crushing of samples at liquid nitrogen temperatures has many applications and has also 
shown to be successful in smaller sized samples, including yeast cells (Yang et al., 2011). 
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5.2.2.2 Choice of lysis reagent 
In the study carried out by de Jong et al. (2010), total RNA was successfully extracted from 
individual zebrafish embryos using QIAzol lysis reagent. In our study, QIAzol was initially 
used as a lysis reagent but was replaced as a precaution with TRI Reagent when RNA 
degradation occurred. TRI Reagent and STAT-60 have been used to extract RNA from 
individual zebrafish embryos in other studies (van der Vaart et al., 2013; Timme-Laragy et 
al., 2012) and it is most likely that using QIAzol after optimisation of the RNA extraction 
protocol would not have affected the yield or quality of samples. 
 
5.2.2.3 Importance of phase separation with small samples  
While it was possible to extract RNA from individual embryos using the TRIzol Reagent 
protocol, the process was not always successful (Figure 4.16). Thus, a method combining 
both TRIzol Reagent and HPLG separation was evaluated. Although only five embryos were 
subjected to each of the two methods, the success rate of purifying RNA from single embryos 
using the combination of TRI Reagent and HPLG separation  appeared to be higher than with 
TRI Reagent alone (Figure 4.1.6). 
 
One difficulty faced when using the TRIzol Reagent protocol was that RNA pellets which 
were precipitated using isopropanol were extremely small in size and often did not pellet 
properly after an ethanol wash step. This could have been due to the limited amount of 
biological sample available from individual embryos, compared to the larger sized adult 
zebrafish livers, where RNA extraction using this protocol was no challenge. Adult zebrafish 
livers can weigh up to 6 mg in males and 13 mg in females (Kan et al., 2009), compared to 
120 hpf embryos which have a dry weight of < 1 mg (personal observation). 
 
5.2.2.4 Importance of column purification with limited RNA 
An alternative strategy to purify RNA was to use the RNA
®
 MinElute
TM 
Cleanup Kit. Instead 
of collecting RNA as a precipitate, RNA bound to a silica-membrane column, washed with 
buffer to remove contaminants such as phenol and proteins, and then collected in an RNase-
free eluate. A possible improvement to extracting total RNA from individual embryos would 
have been to carry out RNA cleanup after separating of RNA, DNA and protein into its three 
phases (by HPLG). It might even be possible to extract RNA without the use of HPLG 
separation, but this has yet to be determined for zebrafish embryos. However, combining both 
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HPLG separation to completely separate limited RNA material and RNA cleanup to purify 
sample has been demonstrated to be successful in obtaining a high yields of RNA. 
 
5.2.3 Evaluation of RNA quality 
One important aspect of RNA extraction is evaluating the yield and quality of the resulting 
ribonucleic acids. This can be achieved by spectrophotometrically measuring the absorbance 
of light at a wavelength of 260 nm (A260), evaluating RNA purity according to its A260/280  
ratio, and assessing RNA integrity by the visualisation of rRNA on denatured agarose gels. 
As mentioned earlier, the ratio between the absorbance of nucleic acids at 260 nm and 280 
nm is often used to determine the purity of material. However the use of the word “purity” is 
often a misnomer when it comes to assessing RNA quality. 
 
“Pure” RNA is said to have an A260/280 ratio between 1.8 and 2.0 (Manchester, 1996). RNA 
has a maximum absorbance at 260 nm and an absorbance of 1.0 corresponds to 40 µg/mL of 
RNA. However, the absorbance at 280 nm can vary, according to the pH, which can be 
affected by contaminants (e.g. proteins) (Wilfinger et al., 1997). For this reason, buffers are 
often recommended for storing RNA, since they stabilise fluctuations in pH. The presence of 
non-RNA material including phenol, ethanol and proteins can also interfere with the 
absorbance values and alter the A260/280  ratio (Fleige and Pfaffl, 2006). In this study, all RNA 
samples were eluted in RNase-free water, and any contaminants affected by pH in the sample 
could have influenced any A260/280 ratios obtaine. In the case of total RNA extracted using the 
TRI Reagent, RNA pellets were washed in ethanol, however additional wash steps could 
have aided in reducing sample contamination and potentially increase the A260/280 ratio. 
Therefore using only this ratio to determine RNA quality is insufficient, but still can give 
some information on the contamination by proteins and phenol within RNA preparations. 
 
Ribosomal RNA constitutes the majority (> 90%) of total RNA. Due to its abundance, rRNA 
will mask other forms of RNA when subjected to denaturing AGE. Thus, the evaluation of 
rRNA quality is used as another means of evaluating of total RNA quality (Sambrook and 
Russell, 2001). Intact rRNA contains the 28S and 18S forms in a ratio of 2.7:1, and the 
presence and intensity of both rRNAs in the denaturing AGE gel can be used to indicate 
whether degradation has occurred in the sample. However, this can also be subjective due to 
the running conditions, the amount of staining agent used and the quantity of RNA subjected 
through the gel. 
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Although extraction was only carried out on a limited number of samples, the A260/280 ratio 
was generally lower compared to total RNA extracted from individual embryos using HPLG 
separation. However, it could be possible that using the TRIzol Reagent protocol leads to a 
final product with residual contaminants, such as phenols and proteins, which might affect 
the interpretation of the values, compared to HPLG separation and column purification which 
help facilitate in giving a more stable, final product. 
 
In the study carried out by de Jong et al. (2010), the quality of total RNA obtained from 
individual zebrafish embryos was determined by its RNA Integrity Number (RIN),  measured 
using a BioAnalyzer (Agilent Technologies). RIN is calculated by an algorithm which takes 
into account the fluorescence of RNA molecules in a sample and their respective sizes. A 
RIN equal or greater than 7.0 is the requirement for high quality RNA, where 10 represents 
intact RNA and 0 completely degraded RNA. The BioAnalyzer is highly sensitive and 
accurate, being able to measure RNA quality in samples with concentrations as low as 25 
ng/µL (Mueller et al., 2004). When the assessment of RNA quality is important (e.g. mRNA 
expression), it is recommended that this technology be utilised for a more objective 
determination of RNA quality, since it minimises any misinterpretations made on RNA 
quality according to A260/280 ratio and rRNA ratio in denaturing AGE. 
 
5.3 Sequencing zebrafish pxr in individuals 
Genetic variation in pxr from different strains of zebrafish has been observed (Bainy et al., 
2013; Lille-Langøy, unpublished data). In order to assess the intraspecies genetic variation of 
the AB/Tu strain, a pxr fragment encoding amino acids from180 to 338 was amplified and 
sequenced from 24 individual zebrafish embryos. The following section will discuss these 
findings in detail and their implications to the overall protein sequence of Pxr. 
 
5.3.1 Absence of genetic variation between individuals 
The region of pxr sequenced across the 24 individuals all contained an identical genotype 
(Figure 4.22). This differed to findings made by Bainy et al. (2013), where three alleles of 
full length zebrafish pxr were identified among individuals of the TL strain, with allelic 
determinants at S184, Y218 and H383. Variants containing S184, Y218 and H383 were 
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designated to possess the pxr*1 allele and variants with I184, C218 and N384 the pxr*2 allele. 
In this study, all individuals contained amino acids corresponding to the pxr*1 allele. 
 
5.3.1.1 Genetic variation dependent on allele frequency 
In this study, pxr was sequenced from only 24 embryos, originating from a mating of ten 
males and ten females. A high number of adults was used for mating in order to maximise 
genetic variation in the offspring, and to increase the likelihood of an allele being detected. 
However, the likelihood of an individual possessing a particular genotype depends on the 
frequency of the allele in the population. For example, if the probability of both allele a (p) 
and allele b (q) in a given population is 0.5, then the likelihood of one of those alleles 
appearing in an individual would have been:                    Of course, these 
probabilities depend on the Hardy-Weinberg equilibrium, where the frequency of all 
genotypes within a population is given by the formula:          . This principle 
assumes that mating is random and that there is no natural selection, mutation or migration 
(Hartl and Clark, 1997). Given subpopulation of 24 individuals, 12 hypothetically would 
have possessed one of each allele. However, if the probabilities were unequal, i.e. if the 
probability of allele a occurring in a given population is 0.9 and allele b is 0.1, then the 
number of individuals possessing only allele b would have been:                 
individual. In light of this, then it may have been difficult to detect alleles in individual 
zebrafish if the frequencies of alleles leading to non-synonymous substitutions were rare. 
 
In a study by (Zhang et al., 2001), 3 non-synonymous alleles were identified in human PXR 
(P27S, G36R and R122Q, Table 5.2). In Caucasians, the alleles giving rise to amino 
substitutions S27, R36 and Q122 occurred in frequencies of 0.00, 0.01 and 0.01 respectively. 
In African Americans, the same substitutions occurred in frequencies of 0.20, 0.03 and 0.00 
respectively. In fact, most identified non-synonymous SNPs appear in very low frequencies 
in human PXR. If allelic determinants are present at such low frequencies, then it is no 
surprise that no alleles in zebrafish pxr were identified in 24 individuals, given the frequency 
of non-synonymous alleles present in human PXR and their probability of occurrence 
assuming Hardy-Weinberg equilibrium. Future studies would benefit from sequencing a 
larger number of individuals.  
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Table 5.2 
12 of the 15 known non-synonymous SNPs identified in human PXR and their respective allele 
frequencies. 
Substitution Sample size Heritage Allele 1 Allele 2 Reference 
E18K 300 Caucasian 1.00 0.00 Hustert et al. (2001) 
 74 African American 0.85 0.15 Hustert et al. (2001) 
P27S 150 Caucasian 1.00 0.00 Zhang et al. (2001) 
 66 African American 0.80 0.20 Zhang et al. (2001) 
G36R 150 Caucasian 0.99 0.01 Zhang et al. (2001) 
 66 African American 0.97 0.03 Zhang et al. (2001) 
R98C 205 Japanese 0.99 0.0024 Koyano et al. (2001) 
R122Q 144 Caucasian 0.99 0.01 Zhang et al. (2001) 
 22 African American 1.00 0.00 Zhang et al. (2001) 
V140M 418 Caucasian 0.99 0.01 Hustert et al. (2001) 
R148Q 205 Japanese 0.99 0.0024 Koyano et al. (2001) 
Q158K 451 Chinese 0.98 0.02 Lim et al. (2005) 
D163G 418 Caucasian 1.00 0.00 Hustert et al. (2001) 
C379G 100 Mixed (93% Caucasian) 1.00 0.005 Bosch et al. (2006) 
R381W 205 Japanese 0.99 0.0024 Koyano et al. (2001) 
I403V 205 Japanese 0.99 0.0024 Koyano et al. (2001) 
 
 
5.3.1.2 Genetic variation between strains 
A major difference between the individuals sequenced in both studies was the strain of the 
fish, with AB/Tu being used in this study and TL being used by Bainy and co-authors. 
Studies comparing genetic variation between species strains have made use of genetic 
markers, which can assess relatedness or differentness between populations. Genetic variation 
between strains of zebrafish can be quite large (Guryev et al., 2006), and it could be possible 
that alleles are more likely to be retained within strains than between them. In a study carried 
out by Coe et al. (2009), the average expected heterozygosity of laboratory maintained 
zebrafish was much lower in the AB/Tu strain (47%) than in wild zebrafish (86%). 
Differences in the degree of heterozygosity indicate that genetic variation differs from strain 
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to strain, and could be why the TL strain studied by Bainy and co-authors might contain 
allelic variants on the pxr gene, while the AB/Tu strain in this study does not, given this is the 
case. 
 
5.3.1.3 Potential conservation in the sequenced region of pxr 
It could be possible that allelic variants exist elsewhere on the pxr gene for the AB/Tu 
individuals. In this study, only 158 of the total 430 amino acids were sequenced in zebrafish 
pxr, and these amino acids encode for the hinge and the beginning of the LBD. In human 
PXR, none of the fifteen SNPs identified overlap with this region of zebrafish pxr sequenced 
in this study (Figure 1.4 & Table 5.2). This could imply that this region (hinge and the 
beginning of the LBD) in both strains remains relatively conserved.  
 
In humans, SNPs have been predicted to occur in approximately 1% of amino acid coding 
sequences, with half of these leading to non-synonymous amino acid substitutions (Hinds et 
al., 2005). SNPs in human PXR have been shown to occur much more frequently in the 5' and 
3'-untranslated regions of the gene, and in introns more than exons (Zhang et al., 2001; Bosch 
et al., 2006). In the case of zebrafish however, the only way to confirm whether the 
sequenced region of pxr is conserved compared to the TL strain sequenced by Bainy et al. 
(2013) would be to sequence this region in other strains, and determine whether commonly 
occurring allelic variants are unique to the TL strain. Another solution would be sequence full 
length zebrafish pxr, to determine whether non-synonymous SNPs are more prevalent in 
other regions of the sequence. 
 
5.3.2 Genetic variation of pxr compared to online sequences and its implications 
When the pxr sequence from this study was compared to two zebrafish pxr sequences 
available on UniProtKB/TrEMBL (identifiers: A5WYG8 and F1R424), six amino acid 
differences were found (Figure 4.22). Five substitutions corresponded to L186V, M202V, 
P208S, N232S and S234T and one insertion to N223. From these two sequences, one was an 
unknown strain (A5WYG8) and the other corresponded to Tu (F1R424). Interestingly, the 
pxr sequence from the Tu strain corresponded to the pxr*2 allele in the TL strain identified 
by Bainy et al. (2013). 
 
Understanding how sequence variation in zebrafish pxr affects target gene expression is 
important if we are to use zebrafish as a model organism. This is especially important in 
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toxicological studies which study the activation of PXR by ligands acting as drugs or 
pollutants. One approach to this would be to clone pxr in the AB/Tu strain from this study, 
the TL strain from Bainy et al. (2013) and the Tu strain identified on UniProtKB and express 
these genes in a reporter assay. The luciferase reporter assay is a well established method in 
our laboratory and allows one to test a nuclear receptor’s LBD ability to be activated by 
various ligands acting as drugs or pollutants. This has been done across a wide range of 
species (Milnes et al., 2008). In fact, using this assay has found that zebrafish pxr variants 
from different strains (AB/Tu, TL and SWT) activate zfPXR in a variant dependent manner 
(Lille-Langøy, unpublished data; Figure B2, Appendix B). These findings could have 
implications on studies that use zebrafish and exposures to compounds acting through PXR. 
 
5.3.3 The detection of SNPs from Sanger sequencing 
Upon initial inspection of the chromatograms of each pxr sequence obtained from Sanger 
sequencing, some individuals exhibited what appeared to be heterozygosity in some of the 
base pairs of their sequence (Figure 4.21). This was indicated by the presence of a twin peak 
in the chromatogram, which appeared to be infrequent and be occurring at random. 
 
A good chromatogram is defined as a sequence that contains evenly-spaced, intense peaks 
corresponding to each base pair and contains minimal baseline noise. Most of the sequences 
in this study had some baseline noise, but were mostly easy to interpret. Chromatograms 
containing weak peaks and high baseline noise will mask low frequency heterozygotes. 
However, from these sequences, no twin peaks corresponding to heterozygotes were 
identified. 
 
As expected, all chromatograms lost intensity further along the sequence. For some 
sequences, this loss in intensity was “top-heavy”, where the intensity of the peaks declined 
very early in the sequence, indicating that the optimal ratio between template and primer was 
not used. However, low baseline noise and evenly-spaced peaks made sequences still 
sufficient to interpret. For this reason, a cut-off point at beginning at V180 and ending V339 
was set to prevent any misinterpretations on questionable regions of the sequence 
 
The presence of twin peaks was only observed when the baseline noise was too strong or 
when the intensity of the actual sequence was weak. This only occurred in a few of the 
sequences and interpretation was still possible but proceeded with caution. Any peaks which 
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suggested the presence of a heterozygote were cross checked with the matching sequence in 
the opposite direction, which were always reliable to interpret. In all instances, the possibility 
of a base pair being heterozygous was ruled out. 
 
5.4 Conclusions 
Five hybridoma supernatants from the spleen cells of mice immunised with human PXR were 
shown to be immunoreactive against the eukaryotically expressed hPXR antigen. Two of 
these supernatants were also found to be immunoreactive againts a protein which could 
potentially correspond to a post-translational modification of PXR. Human PXR was also 
localised in both the cytoplasm and nucleus of transfected COS-7 cells after treatment with 
rifampicin, with a slightly higher concentration in the cyotplasm. In addition, IgG enrichment 
of hybridoma supernatants was shown to lead to an increase in the specificity of 
immunoreactivity of one hybridoma supernatant which had previously been shown to be non-
specific. However, none of the hybridoma supernatants from spleen cells of mice immunised 
with zfPXR were found to be immunoreactive against COS-7 cells transfected with zfPXR or 
against prokaryotic cells expressing the His-tagged zfPXR antigen. Further analyses are 
required in order to determine whether non-specificity is due to antigen problems and/or the 
hybridoma supernatants. 
 
Total RNA was extracted from individual zebrafish embryos using TRI Reagent, HPLG 
separation of phases followed by column purification of RNA. The use of zebrafish embryos 
and a method to extract total RNA from individuals could pave the way for exposure 
experiments where the quantification of genes involved in toxicological response is important. 
 
RNA was obtained at yields high enough for cDNA synthesis and subsequent PCR 
amplification of a region of the zebrafish pxr transcript. We suspected that genetic variation 
in zebrafish pxr could lead to differences in Pxr function. However, no genetic variation was 
found from amino acids 180 to 338 in fragment of pxr sequenced from 24 individuals of the 
AB/Tu strain, despite allelic variants recently being identified in this region of TL strain 
zebrafish. Amino acid differences were found when sequences were compared to an 
unknown and Tu strain of zebrafish submitted to UniProtKB, showing that inter-strain 
variation of zebrafish pxr does exist. These differences could lead to functional variation. 
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Further analyses could focus on sequencing the full length gene from a larger sample size and 
determining if genetic variation exists elsewhere. 
 
5.5 Future perspectives 
One benefit of obtaining highly specific monoclonal antibodies is to utilise them in ChIP 
technology. As mentioned, the first study to utilise this technology using PXR was in mice, 
whereby its DNA-binding sites were investigated after activation with PCN and 
immunoprecipitation using anti-mouse PXR (Cui et al., 2010). However, the induction of 
target genes by PXR depends on the type of ligands which activate the nuclear receptor (Song 
et al., 2004). Therefore this area has potential for further research, especially when 
identifying which target genes become expressed after the activation of PXR by 
environmental pollutants. In addition, producing antibodies specific against PXR in other 
species (e.g. zebrafish) could reveal new target genes not previously attributed to PXR 
activation. 
 
Hybridoma supernatants which have been characterised as immunoreactive against hPXR 
should be studied in further detail. Epitope mapping of the hybridoma supernatants could 
give insight on their exact target of specificity and this could be tested in a number of ways. 
The hybridoma supernatants could be tested again PXR fragments, such as the stable, 
tethered PXR LBD/SRC-1 complex (Wang et al., 2008), or against other PXR fragments (e.g. 
N-terminal, DBD) fused to recombinant proteins which increase their stability. However, 
characterisation against PXR fragments might not give the exact location of the epitope, so 
one alternative is to probe antibodies against a microarray containing thousands of random 
peptides (Linnebacher et al., 2012). Cross-reactivity of the supernatant against one or more of 
the peptides can be traced back to its original sequence and compared against PXR. 
 
Identification of allelic variants in zebrafish pxr was not achieved in this study. Although no 
heterozygous genes were found from Sanger sequencing, it could still be possible that genetic 
variation does exist between individuals. Even if heterozygous alleles did exist, the 
chromatograms of sequences observed in this study were not completely reliable and 
frequently required cross-checking with their reverse complement. Given this degree of 
uncertainty, increasing the number of individuals sequenced could also increase the number 
of false positives. One option worth considering is restriction fragment length polymorphism 
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(RFLP) analysis, whereby a restriction enzyme targeting a site suspected to contain a 
heterozygous allele added to the amplified pxr product (Saiki et al., 1985). Products subject 
to AGE can be used to determine the number of fragments and their respective sizes. Alleles 
in other transcription factors have been identified in this manner, including the Aryl 
hydrocarbon receptor (AhR), which is activated by planar aromatic hydrocarbons including 
planar PCBs (Wirgin et al., 2011). 
 
Given that zebrafish pxr variants can be identified, allelic variants could be used to determine 
whether functional variation exists between alleles. This could be tested by cloning a 
sequence and ligating it into an expression vector. The luciferase reporter gene assay could 
then be used to test whether pxr variants differentially transactivates cyp3a reporter genes 
(Koyano et al., 2004). Additionally, quantification of gene expression from individuals 
exposed to PXR agonists in vivo could elucidate whether differential expression levels of Pxr 
target genes occurs as a result of pxr variation. For example, one could measure cyp3a65 
expression levels in individual embryonic or adult zebrafish exposed to clotrimazole. 
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Appendix A 
 
Table A1 
Protein concentration of COS-7 cell lysate components according to the Bradford protein assay. 
COS-7 cells transfected with Fraction Concentration (µg/ml) 
No plasmid Cytoplasmic 1959 
No plasmid Nuclear 1435 
pSG5 hPXR Cytoplasmic 741 
pSG5 hPXR Nuclear 1096 
pcDNA zfPXR Cytoplasmic 1218 
pcDNA zfPXR Nuclear 1032 
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Table A2 
Concentration and purity of RNA obtained from individual zebrafish embryos using phase lock gel 
separation. 
Individual Concentration (ng / µL) A260/280  Yield (ng)  
1 158.1 1.76 2213 
2 186.2 1.91 2607 
3 140.5 1.89 1967 
4 98.0 2.00 1372 
5 127.7 1.92 1788 
6 202.3 1.98 2832 
7 187.8 1.79 2629 
8 197.1 1.84 2759 
9 178.7 1.93 2502 
10 211.6 1.92 2962 
11 197.4 1.87 2764 
12 168.9 1.96 2365 
13 100.9 1.86 1413 
14 96.8 1.83 1355 
15 144.4 1.89 2023 
16 111.8 1.94 1565 
17 114 1.91 1596 
18 113 1.89 1582 
19 103.6 1.94 1450 
20 126.5 1.91 1771 
21 94.2 1.92 1319 
22 140.7 1.82 1970 
23 90.3 1.92 1264 
24 84.9 1.98 1189 
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Table A3 
Concentration of PCR product (full length zebrafish pxr) obtained after PCR reaction with zfPXR 
primers and cleanup. 
Individual Concentration (ng / µL) A260/280 Yield (ng)  
1 15.2 1.69 760 
2 21.0 1.60 1050 
3 15.4 1.70 770 
4 16.5 1.55 825 
5 14.1 1.75 705 
6 15.3 1.60 765 
7 15.0 2.15 750 
8 16.1 1.88 805 
9 18.1 1.60 905 
10 15.5 1.83 775 
11 14.9 1.57 745 
12 14.1 1.84 705 
13 16.8 1.90 840 
14 15.0 1.88 750 
15 15.3 2.43 765 
16 15.7 1.83 785 
17 14.6 1.54 730 
18 13.1 2.24 655 
19 16.8 2.04 840 
20 15.8 1.66 790 
21 16.2 1.74 810 
22 17.4 1.63 870 
23 14.1 1.94 705 
24 13.7 1.83 685 
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Consensus DNA sequence of pxr (mRNA coding sequence, cds) and translated Pxr in AB/Tu 
strain zebrafish from this study. 
 
GTGTCCGAGTCGAGTCCACTCACAAACGGCAGCTGGATCGATCACAGACCCATCGCTGAAGAC
CCAATGCAGTGGGTCTTCAATCCCACTTCGCTCTCGTCCTCTTCCTCCAGCTACCAGAGCCTT
GACAATAAAGAGAAGAAGCACTTTAAAAGTGGCAACTTCTCCTCTCTGCCACACTTCACAGAC
CTCACCACGTACATGATCAAGAATGTCATCAACTTCGGGAAGACGCTGACAATGTTTAGGGCT
CTGGTTATGGAGGACCAGATCTCGCTGCTGAAAGGTGCCACCTTTGAGATCATTCTGATTCAC
TTCAACATGTTCTTTAATGAAGTGACGGGAATTTGGGAGTGTGGCCCCTTGCAGTACTGCATG
GATGATGCCTTTCGAGCTGGTTTTCAGCACCATCTGCTGGACCCAATGATGAATTTCCATTAC
ACACTGCGTAAGCTGCGTTTGCATGAGGAGGAGTATGTGCT 
 
 
VSESSPLTNGSWIDHRPIAEDPMQWVFNPTSLSSSSSSYQSLDNKEKKHFKSGNFSSLPHFTD
LTTYMIKNVINFGKTLTMFRALVMEDQISLLKGATFEIILIHFNMFFNEVTGIWECGPLQYCM
DDAFRAGFQHHLLDPMMNFHYTLRKLRLHEEEYV 
 
 
Nucleotide sequence of pxr (cds) and amino acid sequence of Pxr in an unknown strain of 
zebrafish from EMBL (DQ069792) and UniProtKB (accession: A5WYG8). 
 
GTGTCCGAGTCCAGTCCAGTCACAAACGGCAGCTGGATCGATCACAGACCCATCGCTGAAGAC
CCAGTGCAGTGGGTCTTCAACTCCACTTCGCTCTCGTCCTCTTCCTCCAGCTACCAGAGCCTT
GACAAAGAGAAGAAGCACTTTAAAAGTGGCAGCTTCACCTCTCTGCCACACTTCACAGACCTC
ACCACGTACATGATCAAGAATGTCATCAACTTCGGGAAGACGCTGACAATGTTCAGGGCTCTG
GTTATGGAGGACCAGATCTCGCTGCTGAAAGGTGCCACCTTTGAGATCATTCTGATTCACTTC
AACATGTTCTTTAATGAAGTGACGGGAATTTGGGAGTGCGGCCCCCTGCAGTACTGCATGGAT
GATGCCTTTCGAGCTGGTTTTCAGCACCATCTGCTGGACCCAATGATGAATTTCCATTACACA
CTGCGTAAGCTGCGTTTGCATGAGGAGGAGTATGTGCT 
 
 
VSESSPVTNGSWIDHRPIAEDPVQWVFNSTSLSSSSSSYQSLDKEKKHFKSGSFTSLPHFTDL
TTYMIKNVINFGKTLTMFRALVMEDQISLLKGATFEIILIHFNMFFNEVTGIWECGPLQYCMD
DAFRAGFQHHLLDPMMNFHYTLRKLRLHEEEYV 
 
 
Amino acid sequence of Pxr in Tu strain zebrafish from UniProtKB (accession: F1R424). 
Nucleotide sequence not available. 
 
VSESIPVTNGSWIDHRPIAEDPVQWVFNSTSLSSSSSSCQSLDKEKKHFKSGSFTSLPHFTDL
TTYMIKNVINFGKTLTMFRALVMEDQISLLKGATFEIILIHFNMFFNEVTGIWECGPLQYCMD
DAFRAGFQHHLLDPMMNFHYTLRKLRLHEEEYV 
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Nucleotide sequence of PXR (cds) and amino acid sequence of PXR in human from EMBL 
(AY091855) and UniProtKB (accession: O75469): 
 
TGCGAGTTGCCAGAGTCTCTGCAGGCCCCATCGAGGGAAGAAGCTGCCAAGTGGAGCCAG
GTCCGGAAAGATCTGTGCTCTTTGAAGGTCTCTCTGCAGCTGCGGGGGGAGGATGGCAGT
GTCTGGAACTACAAACCCCCAGCCGACAGTGGCGGGAAAGAGATCTTCTCCCTGCTGCCC
CACATGGCTGACATGTCAACCTACATGTTCAAAGGCATCATCAGCTTTGCCAAAGTCATC
TCCTACTTCAGGGACTTGCCCATCGAGGACCAGATCTCCCTGCTGAAGGGGGCCGCTTTC
GAGCTGTGTCAACTGAGATTCAACACAGTGTTCAACGCGGAGACTGGAACCTGGGAGTGT
GGCCGGCTGTCCTACTGCTTGGAAGACACTGCAGGTGGCTTCCAGCAACTTCTACTGGAG
CCCATGCTGAAATTCCACTACATGCTGAAGAAGCTGCAGCTGCATGAGGAGGAGTATGTG
CT 
 
 
CELPESLQAPSREEAAKWSQVRKDLCSLKVSLQLRGEDGSVWNYKPPADSGGKEIFSLLP
HMADMSTYMFKGIISFAKVISYFRDLPIEDQISLLKGAAFELCQLRFNTVFNAETGTWEC
GRLSYCLEDTAGGFQQLLLEPMLKFHYMLKKLQLHEEEYV 
 
 
Nucleotide sequence of Pxr (mRNA) and amino acid sequence of PXR in mouse from EMBL 
(AF031814) and UniProtKB (accession: O54915): 
 
TGTGAGCTTCCAGAGTTTCTGCAGGCCTCACTGTTGGAAGACCCTGCCACATGGAGTCAA
ATCATGAAAGACAGGGTTCCAATGAAGATCTCTCTGCAGCTGCGCGGAGAAGACGGCAGC
ATCTGGAACTACCAACCCCCTTCCAAGAGCGACGGGAAAGAGATCATCCCTCTTCTGCCA
CACCTGGCCGATGTGTCAACCTACATGTTCAAGGGCGTCATCAACTTCGCCAAAGTCATA
TCCTACTTTAGGGACCTGCCTATTGAGGACCAGATCTCCCTGCTGAAGGGGGCCACTTTT
GAGATGTGCATCCTGAGGTTCAACACGATGTTCGACACGGAAACGGGAACCTGGGAGTGC
GGCCGGCTGGCTTACTGCTTCGAAGACCCTAATGGTGGCTTCCAGAAACTTCTGTTGGAT
CCATTGATGAAATTCCACTGCATGCTGAAGAAGCTACAGCTGCATAAGGAGGAGTATGTG
CT 
 
 
CELPEFLQASLLEDPATWSQIMKDRVPMKISLQLRGEDGSIWNYQPPSKSDGKEIIPLLP
HLADVSTYMFKGVINFAKVISYFRDLPIEDQISLLKGATFEMCILRFNTMFDTETGTWEC
GRLAYCFEDPNGGFQKLLLDPLMKFHCMLKKLQLHKEEYV 
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Appendix B 
 
The following supplementary data was taken from the Master’s thesis of Richard Davies 
(Figure 4.11, 2011). Note that SXR refers to PXR, immunogen means antigen, and that 
hybridoma supernatant 12D5B5C8 was also tested in our study. 
 
 
Figure B1. Immunoreactivity of hybridoma supernatants against hSXR and zfSXR 
orthologs. 300 μg of PXR was separated using a 10% SDS-PAGE gel and transferred to a PVDF 
membrane. The membrane was cut into strips prior to screening. The primary antibody probes were 
non-diluted hybridoma culture supernatants 9f10f2c7, 5e4f9d9, 1c11e7e10, 8e2b8f4, 12d5b5c8, 
7b10d2c4, 9e11e4f7 and 8f11e8e11 as well as HT medium (no dilution) and anti-hist mAb (1:3000). 
The supernatants were used to probe the immunogen used in their development (a) and an immunogen 
containing SXR from a different species (human or zebrafish) (b). Primary Antibodies were detected 
with polyclonal goat anti-mouse Ig HRP-conjugated antibodies. Respective protein sizes in kDa are 
labelled on the left of the figure as indicated by a Precision Plus Protein Standard. Development was 
by Amersham ECL Plus
TM
. 
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The following supplementary data was taken from work carried out by PhD candidate Roger 
Lille-Langøy (unpublished data). 
 
 
Figure B2. Luciferase reporter gene assay of zebrafish pxr variants after exposure to 
clotrimazole. Ligand activation was reported as a fold change of luciferase activity relative 
to vehicle control (DMSO). Transfection efficiency was normalised against β-galactosidase 
activity. Concentrations range from 10 nM to 6 µM, with data points representing the mean 
of individual triplicate experiments ± standard deviation.  
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Figure C1. Poster presented at the Norwegian Society for Pharmacology and Toxicology 
(NSFT) winter meeting in Beitostølen 2014. 
Appendix C 
 
